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The current generation of designer drugs of abuse are synthetic analogues of the stimulant 
cathinone. Popularly known as ‘bath salts’, these drugs are marketed as safer (and often 
legal) alternatives to known psychoactive drugs like methamphetamine, cocaine, and ecstasy. 
There is emerging literature on the pharmacology and toxicology of these ‘bath salts’, though 
to date few scientific studies have specifically examined the behavioural sequelae. The 
current study therefore sought to assess some of the behavioural effects of mephedrone, one 
of the most common primary active ingredients of ‘bath salts’. Male and female hooded rats 
were used in three experiments examining anxiety-like behaviours in a number of established 
behavioural testing paradigms. Experiment 1 examined the dose-response relationship and 
found that mephedrone produced more anxiety-like behaviours as dose increased, though 
interestingly only for female rats (males instead displayed an inverted ‘U’ shaped dose-
response curve). A large number of stereotyped behaviours were observed at high doses so 
this was examined in Experiment 2. It was found that as mephedrone dose increased, so too 
did the frequency of stereotyped behaviours, though this finding also differed across the 
sexes in its presentation (males tended to exhibit more non-ambulatory behaviours such as 
head swaying whereas females tended to display more locomotor stereotypies). Experiment 3 
examined the adolescent behavioural teratology of mephedrone by chronically treating rats 
during adolescence, and then later testing them in adulthood. Results showed that adolescent 
mephedrone use increased anxiety-like behaviours later in life, though there was some 
evidence that this effect could be mitigated by environmental enrichment. Taken together, the 
findings of this study suggest that mephedrone is a powerful anxiogenic compound capable 
of producing behavioural changes following both acute and chronic administration. Of 
particular interest and concern is the different presentation of effects noted in male and 




1.0 General Introduction 
 The use and abuse of psychoactive compounds is a significant and all-to familiar 
problem for communities and governments around the world today. New ‘designer drugs’ 
produced to mimic the effects of known illicit substances are created at an alarming rate, and 
often legislative bodies, not to mention medical professionals, are left scrambling to ‘catch 
up’ after the fact. This ‘cat and mouse’ of drug creation and sale, constantly preceding 
legislation and understanding the known effects leads to a situation where unsuspecting 
people can purchase and consume substances, often legally, under the impression that they 
are well-tested and safe; an impression that is often far from reality. The so-called ‘legal 
high’ industry has evolved from the development of synthetic derivatives of fentanyl in the 
early 1980s, phenethylamines in the late 1980s, tryptamines in the 1990s, piperazines in the 
2000s, to the current trend of synthesizing cathinone derivatives (Brandt, Freeman, Summale, 
Measham, & Cole, 2010; Coppola & Mondola, 2012a). These synthetic cathinones, 
commonly referred to as ‘bath salts’, are molecular analogues of amphetamine and have been 
said to possess the worst characteristics of methamphetamine, cocaine, lysergic acid 
diethylamide (LSD), phencyclidine (PCP, or ‘angel dust’), and 
methylenedioxymethamphetamine (MDMA, or ‘ecstasy’) (Ross, Watson, & Goldberger, 
2011). Bath salts are sometimes referred to as psychoactive bath salts (PABS) in order to 
differentiate them from the legitimate bathing products (magnesium sulphate crystals or 
‘Epsom salts’ dissolved in bath water for cosmetic purposes; i.e., to improve cleaning, soften 
the skin, or for their aroma) whose name they have inaccurately taken (Browning, 1999; Ross 
et al., 2011). They describe a family of drugs whose active ingredients are one of several 
synthetically derived cathinone analogues, typically 3,4-methylenedioxypyrovalerone 
(MDPV) or 4-methylmethcathinone (mephedrone) (ACMD, 2010; Harvey & Baker, 2015; 




This paper will examine the current literature on ‘bath salts’ with a specific emphasis 
on mephedrone, the variety thought most common in European countries and in New Zealand 
(Brandt et al., 2010; Farrier, 2010; Wood & Dargan, 2012). A note on terminology: the term 
‘bath salts’ (the origins of which are explained in the next section) is popularly used to 
individually describe mephedrone, MDPV, methylone, and a number of other synthetic 
cathinone derivatives. For the purposes of this paper, the term ‘bath salts’ may be used 
synonymously with ‘synthetic cathinones’ (i.e., the class of drug that contains mephedrone, 
MDPV, and others). The individual drug’s name will be used when referring to a specific 
compound (e.g., ‘mephedrone’).     
1.1 Origin of “Bath Salts” 
 Cathinone is a naturally present alkaloid found in the Khat plant (Catha edulis), a 
leafy evergreen shrub native to several regions of Africa and the Arabian peninsula 
(Cameron, Kolanos, Vekariya, De Felice, & Glennon, 2013; McClean, Anspikian, & Tsuang, 
2012). Locally the leaves of the khat shrub have traditionally been chewed or boiled in a tea 
to produce stimulation and a state of euphoria (Ali et al., 2010; Coppola & Mondola, 2012a; 
Kalix, 1986). Chewing the leaves for approximately one hour produces psychotropic effects 
that last for around 3 hours thereafter (Kalix, 1996). Cathinone exerts its effects on the brain 
by releasing catecholamines from pre-synaptic storage sites in the central and peripheral 
nervous system (Kalix, 1986), and it is also thought that it may act as a monoamine oxidase 
inhibitor, preventing the breakdown of monoamine neurotransmitters at the synapse and thus 
increasing their availability (Nencini, Amiconi, Befani, Abdullahi, & Anania, 1984). The 
World Health Organisation (WHO) classifies khat as a ‘drug of abuse’ (Nutt, King, 
Saulsbury, & Blakemore, 2007), and cathinone has ‘Schedule 1’ drug status under the 




 The first synthetic cathinones were methcathinone and mephedrone, produced as early 
as the late 1920s. However, with few (if any) therapeutic applications, and serious side 
effects noted, these drugs fell out of favour and common use for decades. It was only in the 
2000’s that they re-emerged as designer drugs of abuse, and became popular in the ‘legal 
high’ arena as recreational/party drugs (Coppola & Mondola, 2012b; Karila, Megarbane, 
Cottencin, & Lejoyeux, 2015). More recently, the first synthetic cathinone to come to the 
attention of European authorities was mephedrone, in 2007 (German, Fleckenstein, & 
Hanson, 2014; Karila et al., 2015; McClean et al., 2012). In the following years mephedrone, 
MDPV, and other synthetic cathinones received a surge of popularity in Europe and the USA 
(Dargan, Sedefov, Gallegos, & Wood, 2011; McClean et al., 2012; Wieland, Halter, & 
Levine, 2012). By 2010 mephedrone had been detected in 28 European countries (Karila et 
al., 2015) and a number of international governments were considering legislation to ban its 
use (ACMD, 2010).  
The delay in implementing controls for these drugs was likely due in no small part to 
the tactics used by the developers: the drugs were marketed online and sold in head shops, 
petrol stations, and conveniences stores as ‘bath salts’ and labelled “not for human 
consumption” in an attempt to circumvent federal drug-analogue laws (Goshgarian, Dawn, & 
Caplan, 2011). Other surreptitious attempts to avoid regulatory scrutiny saw them sold as 
other innocuous substances such as ‘plant food’ and ‘fertiliser’ (Borek & Holstege, 2012). 
These false bath salts were similar in appearance to genuine bath salts (fine white powder or 
crystals) and were sold in small individual sachets with brand names like ‘Ivory Wave’, 
‘White Lighting’, ‘Vanilla Sky’, and ‘Cloud 9’. Their ready availability (particularly over the 
internet), low price, and the fact that they were marketed as safe and legal alternatives to 
other drugs of abuse led to a surge in their popularity, particularly among young people 




legislation rendering the spurious labelling redundant, the term ‘bath salts’ has remained, 
becoming synonymous with this growing group of synthetic cathinone derivatives.            
1.2 Pharmacokinetics 
 Bath salts are generally sold as a white crystalline powder and can be taken 
intranasally (snorting), orally, intravenously, intramuscularly, or rectally (Dargan et al., 
2011). In a 2011 survey of nearly 1000 mephedrone users in the UK, the most popular 
method of administration was snorting (65.9%), though the authors noted that many of these 
users reported significant nasal irritation, which in turn led to a change from nasal to oral 
administration (Winstock et al., 2011). Additionally, oral users have reported that the powder 
has an unpleasant taste, so oral administration is usually achieved by dissolving the powder in 
water, ‘pressing’ the powder into tablets, or wrapping the powder in cigarette paper and 
swallowing (‘bombing’) (Dargan et al., 2011). The white powder is easily soluble in water 
making injection another viable administration route. Bath salts appear to be psychoactively 
effective at doses as low as 3-5mg, with typical doses being between 5 and 250mg per 
session (Dargan et al., 2011; Pasties, 2010; Ross et al., 2011). Users report initially using 
lower doses (50-75mg) then increasing quickly to doses in the hundreds of milligrams 
(Newcombe, 2009). In the UK clubbers’ survey, 22.3% of participants reported using more 
than 1 gram in a typical session (Winstock et al., 2011). Intravenous mephedrone use is 
associated with higher doses, more frequent use, and an elevated psychiatric symptom profile 
(Kapitany-Foveny et al., 2015). The onset of action depends on the method of administration 
and is usually between 15 to 45 minutes when taken orally, and within minutes for nasal 
insufflation, with peak effects after 30 minutes (McClean et al., 2012). Despite mimicking the 
effects of known stimulants bath salts are not usually detected in regular urine analysis 
(Winder et al., 2013). Successful detection in hair or urine samples requires gas 





 1.3.1 Desired effects. Synthetic cathinones are structurally similar to amphetamine, 
MDMA, and cocaine and thus produce stimulant and sympathomimetic effects comparable to 
these compounds (ACMD, 2010; Gatch, Rutledge, & Forster, 2015; Varner et al., 2013; 
Wieland et al., 2012; Winstock, Marsden, & Mitcheson, 2010). The desired effects for which 
they are taken include euphoria, elevated mood, improved mental function, increased 
sociability, enhanced appreciation of music, and mild sexual stimulation (ACMD, 2010; 
Dargan et al., 2011; Winstock et al., 2011). Users report that the ‘high’ associated with 
mephedrone use is better and longer-lasting than that of cocaine (Winstock et al., 2011). The 
desired effects are said to last for around 2 to 4 hours, while some secondary effects such as 
mild stimulation, hypertension, and tachycardia can last for over 8 hours (Dargan et al., 2011; 
DEA, 2011; Martinez-Clemente et al., 2013).    
 1.3.2. Side effects. While the scientific literature is still relatively sparse on the side 
effects of using bath salts there is a significant body of information comprised of case studies, 
emergency room reports, and calls to poison control centres. There are documented cases of 
bath salts users experiencing severe paranoid psychosis (Antonowicz, Metzger, & 
Ramanujam, 2011; Goshgarian et al., 2011; Kasick, McKnight, & Klisovic, 2012; McClean 
et al., 2012; Striebel & Pierre, 2011), hallucinatory delirium (Penders & Gestring, 2011), 
extreme agitation and violent behaviour (Penders, Gestring, & Vilensky, 2012), confusion, 
syncope, and tachycardia (Smith, Cardile, & Miller, 2011; Wood et al., 2010), serotonin 
syndrome (Mugele, Nanagas, & Tormoehlen, 2012), and hyperthermia leading to multiorgan 
system failure and death (Borek & Holstege, 2012). Table 1 presents a list of possible effects 









Physical and Behavioural Effects of Bath Salts (Ross et al., 2011)  
Physical Effects Behavioral and Mental-Status Effects 






Mydriasis Aggressive behavior 
Muscle tremor and spasms  Violent behavior 
Seizures Self-destructive behavior 
Stroke Self-mutilation 
Cerebral edema  Suicidal ideation 
Respiratory distress  Insomnia 
Cardiovascular collapse  Anorexia 
Myocardial infarction  Depression 
Death  
  
1.3.3 Mode of action. Synthetic cathinones generally act as central nervous system 
stimulants by blocking the reuptake of monoamines in the brain, thereby increasing the 
concentration of neurotransmitters like dopamine, serotonin, and norepinephrine at the 
synapse (Coppola & Mondola, 2012b). The specific mechanism of action varies between 
compounds, and is generally produced either by blocking uptake (as with cocaine), or by 
acting as a transporter substrate and evoking the non-exocytotic release of transmitters from 
the pre-synaptic neuron via a process of reverse transport (as with amphetamine) (Baumann 
et al., 2012; Baumann et al., 2013; Cozzi, Sievert, Shulgin, Jacobill, & Ruoho, 1999; 
Eshleman et al., 2013; Nagai, Nonaka, & Kamimura, 2007; Schifano et al., 2011; Simmler et 
al., 2013). They produce the same CNS arousal as cocaine, amphetamines, and MDMA, 
though as their molecules are less lipophilic they are less able to cross the blood-brain barrier 
(although MDPV in particular is more able to cross the blood-brain barrier than other 
synthetic cathinones) (Coppola & Mondola, 2012a; Winder et al., 2013). The effects of bath 
salts appear to be dose-dependant, with MDPV being described as having stimulant effects 




(Coppola & Mondola, 2012b; Zourob, 2011). The presence of a ketone on the molecule’s 
structure reduces its central nervous system penetration and potency, and as a result users 
must consume a greater quantity of the compound (than amphetamine, for example) to 
achieve a similar effect. With greater quantities however, come more pronounced adverse 
effects and a greater abuse potential (Hill & Thomas, 2011; Winder et al., 2013). 
 1.3.4 Toxicology. Unfortunately, much of the evidence for the toxicological effects of 
bath salts has to date relied largely on self-report data and often cannot explicitly rule out 
other confounding variables (e.g., poly-drug use, incorrect drug identification, co-morbid 
medical or psychological conditions) (ACMD, 2010; Coppola & Mondola, 2012b; Dargan et 
al., 2011). The effects of acute toxicity appear to depend on the dose and frequency of use, 
and can include symptoms such as: psychomotor agitation, motor automatisms, 
parkinsonism, tremors, tachycardia, chest pains, hypertension, hyperthermia, mydriasis, 
dizziness, delusions, paranoid psychosis, depression, panic attacks, discolouration of the skin, 
long-term changes in cognition and emotional stability, rhabdomyolysis, abdominal pain, 
vomiting, kidney damage, hyponatremia, headache, cerebral edema, seizures, suicidal 
ideation, excited delirium, and severe insomnia (Baumann, 2014; Borek & Holstege, 2012; 
Coppola & Mondola, 2012b; Dargan et al., 2011). In hospitals acute toxicity is typically 
treated with benzodiazepines (to control agitation and seizures) and antipsychotics (to control 
severe agitation and psychotic symptoms). Hyperthermia is treated with aggressive cooling, 
and hyponatremia is treated with hypertonic saline and water restriction (Coppola & 
Mondola, 2012b; McClean et al., 2012; Spiller, Ryan, Weston, & Jansen, 2011). 
 There have been few studies to date looking into the potential long-term toxicity of 
bath salts (ACMD, 2010). One study by den Hollander et al. (2013) looked at the possible 
long-term behavioral effects of mephedrone on mice. They found that working memory 




‘binge-like’ regimen of mephedrone. This suggests that long-term sequelae of repeated bath 
salt use may indeed be a concern, though more research in this area is needed. 
 1.3.5 Fatalities. There have been a number of high-profile deaths reported in the 
media that have been ‘linked’ to bath salts, though in several of these cases the deaths have 
later been shown to be the result of other causes (or at least not solely due to bath salts, i.e., 
poly-drug use was involved) (Coppola & Mondola, 2012b; Dargan et al., 2011). Even so, 
there is a growing body of evidence reporting a number of deaths that are the direct result of 
synthetic cathinone use, usually attributed to cerebral edema (ACMD, 2010; Dargan et al., 
2011; Maskell, De Paoli, Seneviratne, & Pounder, 2001).   
1.4 Abuse Potential 
 Bath salt users have described strong cravings to re-use the drug and a number of 
researchers have found synthetic cathinones to have a similar abuse potential to 
amphetamines and MDMA (ACMD, 2010; Bonano, Glennon, De Felice, Banks, & Negus, 
2014; Coppola & Mondola, 2012b; Creehan, Vandewater, & Taffe, 2015; Gatch et al., 2015; 
Hadlock et al., 2011; Hutsell et al., 2015; Schindler et al., 2015; Wood & Dargan, 2012). 
Mephedrone has been shown to have strong reinforcing properties, and is readily self-
administered by rats (Aarde et al., 2013; Hadlock et al., 2011; Motbey et al., 2013). In a 
survey of poly-drug users, users of mephedrone were as likely as users of MDMA to self-
report three or more DSM-IV symptoms of substance dependence (Uosukainen, Tacke, & 
Winstock, 2015). 
In an experimental study by Lisek et al. (2012) acute mephedrone administration 
increased ambulatory activity in rats, consistent with the expected effects of similar 
psychostimulants. They found that ambulation was inhibited with pre-treatment with a 
dopamine D1 antagonist and enhanced with pre-treatment with a dopamine D2 antagonist. 




following 10 days of abstinence and they displayed sensitization to the psychomotor 
stimulant effects. Lisek et al. (2012) also performed conditioned place preference tests and 
found that mephedrone conditioning resulted in a preference shift for both rats and mice. 
They conclude from their study that their findings suggest an ‘abuse liability’ of bath salts 
similar to established drugs of abuse. In a similar study Gregg, Tallarida, Reitz, McCurdy, 
and Rawls (2013) also concluded that mephedrone produced sensitizing behavioural effects, 
though they found said effects to be weaker than those of established psychostimulant drugs. 
 Similar conclusions of abuse potential were drawn from a study by Robinson, 
Agoglia, Fish, Krouse, and Malanga (2012). In their experiment they compared mephedrone 
to cocaine in an intracranial self-stimulation (ICSS) paradigm in rats. After intraperitoneal 
administration of saline, mephedrone, or cocaine, rats were placed in an operant chamber 
with electrodes in their lateral hypothalamus. ICSS responding was monitored to gauge the 
effect each drug had on brain reward systems. They found that both mephedrone and cocaine 
dose-dependently decreased the half maximal responding threshold and the brain stimulation 
reward threshold of the rats. In addition, mephedrone also lowered the maximum responding 
rate, whereas cocaine did not. These findings suggest that mephedrone has similar effects to 
cocaine on reward systems in the brain; though interestingly the results from mephedrone 
treated rats only began 15 minutes after administration, indicating that it has a slower onset of 
action. 
 A further animal study compared methamphetamine, MDPV, MDMA, and 
mephedrone in their acute effects on locomotor wheel activity in rats (Huang et al., 2012). 
Results from this study found that MDPV was comparable to methamphetamine (they both 
produced a biphasic change in the pattern of wheel rotations after administration), whereas 
mephedrone was more comparable to MDMA (their observed reduction in wheel counts was 




effects of bath salts may be specific to the particular active ingredient used: MDPV may be 
primarily a psychomotor stimulant like methamphetamine, and mephedrone may be more 
like an entactogen, such as MDMA (ecstasy). 
 There is evidence to suggest that frequent use of high doses of bath salts can cause 
tolerance, dependence, craving, and withdrawal symptoms following cessation (Coppola & 
Mondola, 2012b). The most common withdrawal symptoms for mephedrone include fatigue, 
insomnia, nasal congestion, and impaired concentration; though they can also include 
depression, anxiety, increased appetite, irritability, unusual sweat odour, and urge/craving for 
use (Marsden et al., 2011; McClean et al., 2012). 
 Dargan et al. (2011) suggest that physical dependence on mephedrone is “unlikely” 
given its particular pharmacology. Instead, they suggest that any dependence-like syndrome 
and withdrawal symptoms are psychologically based (though they may require medical 
treatment). This view may also be supported by an experiment conducted by Angoa-Perez et 
al. (2012). In their study they found that mephedrone increased locomotor stimulation and 
hyperthermia in rodents, similar to amphetamines, though surprisingly it did not cause 
neurotoxicity to the dopamine nerve endings in the striatum (as methamphetamine does). 
This may suggest that mephedrone, while producing many of the same behavioural and 
physiological effects as amphetamine, does not pose the same physiological risk from long-
term repeated use. 
 Given the frequency of poly-drug abuse amongst users, Berquist, Peet, and Baker 
(2015) tested mephedrone’s ability to increase sensitisation to other drugs (namely, 
amphetamine). They found that rats treated with both mephedrone and amphetamine had 
significantly higher behavioural sensitisation indices compared to those treated with either 




‘wash out’ period. This finding suggests that mephedrone use may enhance sensitivity to the 
behavioural effects of amphetamine. 
1.5 Conclusion 
 Although most countries now have legislation banning the use of synthetic cathinones 
or ‘bath salts’, their sale and distribution is still commonplace. These drugs are relatively 
cheap and easy to acquire and are believed by many users to be safer (if not legal) 
alternatives to ‘traditional’ illicit drugs (like methamphetamine and ecstasy). Comparatively 
little is known about the effects and methods of action of bath salts, as research in this area 
has only recently begun to contribute to our knowledge base. What we know already suggests 
that while these drugs may be analogous to known psychoactive substances they are also 
different enough to defy some obvious expectations. That these drugs can be so easily 
obtained and used is of great concern, as their full impact both on the user and those around 
them is not yet known. Already bath salts have been implicated in a number of horrific high-
profile crimes such as the case of a homeless Miami man caught allegedly attacking another 
man and eating his face (ABC News, 2012).   
The suggestion that current knowledge makes is that bath salts likely have similar 
abuse potential to known drugs of abuse. There is little empirical evidence of this yet 
however, with most of the literature currently comprised of self-report data, emergency room 
reports, and poison control center call logs. The literature is filled with anecdotal evidence 
and case studies and it is critical that this evidence is tested in controlled experiments. It is 
important that we better understand what these drugs do, how they work, and what potential 
problems users might face (such as dependence and addiction). It is similarly crucial that 
public knowledge of these drugs is increased, because several commonly held beliefs about 





1.6 The Current Study 
 The current study was designed to contribute to the emerging, collective knowledge 
about bath salts, specifically the drug mephedrone. The scientific literature examining the 
effects of this drug is currently sparse relative to that of many more established illicit drugs, 
and this potentially has an impact on the ability of legislators and health professionals to 
combat and respond to what is a disturbing trend. Much of the current literature has a focus 
primarily on the neuro-pharmacological and toxicological effects, with little research into the 
behavioural sequelae of mephedrone use. Therefore, the current researcher chose to focus this 
study on the behavioural pharmacology of mephedrone over the course of three experiments. 
Using established animal models; Experiment 1 looks at the effects of mephedrone on 
anxiety-like behaviour in male and female hooded rats, including investigating the dose-
response relationship. Experiment 2 assesses the effect of mephedrone on stereotypy; the 
persistent, repetitive behaviours observed in Experiment 1. And Experiment 3 looks at the 
potential long-term behavioural teratological effects of adolescent mephedrone use, and to 
what extent these effects can be mitigated by environmental enrichment. It is hoped that the 
combined findings of these three experiments will contribute a greater understanding of the 












2.0 Experiment 1 – Dose-Response Analysis 
2.1 Anxiety - Overview 
Anxiety is a commonly reported side effect of stimulant abuse and is well represented 
in the current toxicology literature as an effect of using mephedrone (e.g., ACMD, 2010; 
Dargan et al., 2011; Ross et al., 2011). In humans, anxiety is considered a psychological 
condition characterised by tension, expectation of an impending threat or disaster, and 
continuous vigilance for danger (Carlson, 2010). Exposure to anxiety-inducing stimuli causes 
activation of the sympathetic division of the autonomic nervous system, commonly referred 
to as the ‘fight or flight’ response (Cannon, 1963). In this state the body draws on stored 
energy reserves, releases epinephrine, and increases blood flow to the skeletal muscles in an 
effort to prepare itself for the physical demands of fighting or running away. ‘Non-critical’ 
systems (systems not contextually critical for assisting in an acute danger situation) like 
digestion are decreased to devote all possible resources to dealing with the current ‘threat’. 
Once the danger has subsided, the parasympathetic nervous system (sometimes called the 
‘rest and digest’ system) decreases heart rate and increases digestion, returning the body to its 
normal state of homeostasis (Carlson, 2010). The physical symptoms associated with anxiety 
can include shortness of breath, excessive sweating, irregular heartbeat, dizziness, fainting, 
and feelings of unreality. Psychological symptoms can include excessive worry, restlessness, 
irritability, poor concentration, and difficulty sleeping (Carlson, 2010; MHFNZ, 2016). 
Behaviourally, anxiety is associated with withdrawal and avoidance behaviours as people 
often try to alleviate their discomfort by removing themselves from the anxiety-inducing 
situation entirely (Friedman & Silver, 2006). 
2.2 Animal Models of Anxiety 
 It is commonly held that anxiety in rodents is a comparable experience to that in 




physiological changes are triggered in the body, which in turn usually result in behaviour or 
behaviours intended to either remove the threat or remove oneself from the threat. These 
habits are observable in rats, which predictably exhibit anxiety-like behaviours, in response 
to threatening stimuli (e.g., an aversion to high, open spaces) (Palanza, 2001).  
In behavioural testing, animal models of anxiety are typically comprised of either 
conditioned models or unconditioned models. Conditioned models involve training or 
conditioning the animals to respond to changes in their environment such as electric shocks, 
loud noises, or food or water deprivation (Rowse, 2010). These models are relatively time 
consuming, resource-intensive, and more invasive as the animals must be conditioned prior to 
testing, often over a period of days or weeks. Unconditioned models do not require any 
special training or manipulation to the animals; instead, they are observed more organically 
in situations that naturally induce an anxiety-like response (e.g., heights, bright lights, and 
open spaces) (Palanza, 2001). Many of these models exploit the natural conflict animals like 
rats have between their innate predisposition to explore novel environments, and their 
aversion to anxiety-producing situations. Common examples of behavioural tests for anxiety 
in rats include: 
 2.2.1 Open Field Test. Originally constructed as a large circular apparatus the ‘open 
field’ is now more commonly represented as a rectangular or square, lid-less box with a grid 
design on the floor. When placed in the apparatus the rat faces a conflict between their 
natural tendency to explore a novel environment, and their aversion to being ‘vulnerable’ in a 
wide, open space. As a result it is possible to both observe the rat’s locomotor activity over 
time, and to infer its degree of anxiety based on its relative movements either in the inner grid 
squares (suggesting a less-anxious rat, content to explore the open areas) or the outer grid 
squares (suggesting a more anxious rat, keeping to the relative ‘shelter’ of the apparatus’ 




 2.2.2 Light/Dark Box Test. Constructed as a dual-compartment, enclosed box, this 
apparatus contains a ‘light side’ (a compartment painted white, with bright light entering) and 
a ‘dark side’ (a second compartment painted black, and darkened from any light source). 
When placed into the apparatus with free access to either side, the rat is faced with a conflict 
between its natural tendency to explore a novel environment, and its aversion to bright lights. 
The rat’s degree of anxiety can then be inferred by the number of entries it makes into, and 
relative time spent in the ‘aversive’ light side (Bourin & Hascoet, 2003). 
 2.2.3 Elevated Plus Maze Test. Constructed as a plus shaped wooden maze and 
raised off the ground, the elevated plus maze apparatus is comprised of two closed arms 
(arms with high sides so the rat cannot escape) and two open arms (arms with no sides, so the 
raised arms are suspended over open space). When placed in the apparatus the rat is faced 
with a conflict between its natural tendency to explore a novel environment, and its innate 
fear of open and elevated spaces. The rat’s degree of anxiety can be inferred by the number 
of entries into, and relative time spent in each of the arms (closed arms suggest more anxiety, 
open arms suggest less) (Silva & Brandao, 2000). 
2.3 Sex Differences 
 In humans there are a number of sex differences noted in the prevalence, aetiology, 
and presentation of most psychological disorders (APA, 2013). In terms of anxiety there is a 
well-documented sex disparity for the prevalence of anxiety disorders, with females 
experiencing these syndromes nearly twice as often as males (Kokras & Dalla, 2014; 
Nemeth, Harrell, Beck, & Neigh, 2013). In spite of this accepted phenomenological fact the 
overwhelming majority of animal models of anxiety (and other disorders) have used only 
male subjects. This potentially brings in to question not only the generalisability of the 
studies’ findings, but also the validity of the animal models themselves for examining female 




attempted to observe sex differences in anxiety have often yielded inconsistent results and 
been unable to draw firm conclusions about which sex was more anxious (Johnston & File, 
1991; Rowse, 2010). Females are typically more active in behavioural tests, and this 
significant difference in locomotion between the sexes can potentially be a confounding 
variable when trying to infer anxiety-like behaviours (Kokras & Dalla, 2014).       
2.4 Known Effects of Other Stimulants 
 While no behavioural studies currently exist examining the effects of mephedrone on 
anxiety in rats, there have been a number of studies looking at the effects of similar 
stimulants of abuse. Methamphetamine, MDMA, cocaine, methylone, and benzylpiperazine 
(BZP) have all been shown to produce an observable anxiogenic effect (i.e., increased levels 
of anxiety relative to a saline control) in similar behavioural tests (Aitchison & Hughes, 
2006; Daniel & Hughes, 2016; den Hollander et al., 2013; Pometlova, Nohejlova-Deykun, & 
Slamberova, 2012; Quinteros-Munoz et al., 2010; Thompson, 2012; Yang, Gorman, Dunn, & 
Goeders, 1992). 
 2.4.1 Dose-response relationships. When trying to understand new drugs on the 
market it is important to investigate their effects not only globally, but also how those effects 
may change at different doses of the drug. Sometimes a drug can be beneficial at low doses, 
but dangerous or even lethal at high doses. The beneficial effects may increase as the dose 
increases, or they may plateau (or even reverse) after a particular dose strength. The 
relationship between the dose and the subsequent effect(s) is commonly known as the ‘dose-
response relationship’ (Moroney, 2016). Previous research has shown the dose-response 
relationship for the effect of similar stimulant drugs (e.g., caffeine, methamphetamine, and 
methylphenidate) on locomotor activity to be an inverted ‘U’ shaped curve (initially an 
increase in activity as drug dose increases, then a decrease) (Clemens, Cornish, Hunt, & 




2.5 Experiment 1 Aims and Hypotheses 
 Experiment 1 sought to examine the effects of mephedrone on anxiety-like behaviours 
in male and female hooded rats. While the scientific literature on the behavioural effects of 
mephedrone is still quite sparse, much of our current knowledge suggests that it behaves 
analogously to known stimulants like methamphetamine. As these stimulants have been 
shown in previous animal studies to be anxiogenic, it was hypothesised that mephedrone 
would similarly increase anxiety-like behaviours in rats, relative to saline controls. 
Additionally, Experiment 1 sought to investigate the dose-response relationship of 
mephedrone on anxiety-like behaviours. Using an increasing range of doses (1mg/kg, 
20mg/kg, 40mg/kg, and 60mg/kg) as well as a saline control group, it was hypothesised that 
mephedrone would produce an inverted ‘U’ shaped curve (an initial increase in observable 
anxiety-like behaviours, followed by a decrease) similar to previous results from tests with 


















 The subjects used in this study were 50 male and 50 female PVG/c hooded rats bred 
in the Animal Facility of the Department of Psychology at the University of Canterbury, 
Christchurch, New Zealand. Following weaning at PND30 (Postnatal day 30) the animals 
were housed in 525 x 330 x 230mm-high plastic cages in groups of three or four same-sexed 
animals. They were kept on a 12-hour light/dark cycle (lights on at 0800 hours) at an ambient 
temperature of 22 ± 2°C (with humidity of 48% ± 10%). All subjects had free access to 
standard laboratory food and drinking water at all times. The care and experimental treatment 
of subjects complied with Parts 5 (Code of Welfare) and 6 (Use of Animals in Research, 
Testing and Teaching) of the New Zealand Animal Welfare Act, 1999 and had been approved 
by the Animal Ethics Committee of the University of Canterbury (See Appendix A). 
3.2 Mephedrone Treatment 
  The subjects were randomly assigned to one of five drug treatment conditions, with 
each condition containing 10 male and 10 female subjects.  The conditions were: 1mg/kg, 
20mg/kg, 40mg/kg, or 60mg/kg of mephedrone, and a saline control group. This dose range 
was selected to approximate the range of dosages commonly used in the existing literature 
(e.g., den Hollander et al., 2013; Lisek et al., 2012; Marusich, Grant, Blough, & Wiley, 
2012). The mephedrone used in this study was synthesised on-site in the Department of 
Psychology at the University of Canterbury. The resulting mephedrone 98% salt was 
dissolved daily in isotonic saline to create solutions of the various dosages. These doses were 
then administered to the subjects via intraperitoneal (I.P.) injections in a volume of 1ml/kg.  
At approximately PND100 (adulthood) subjects received treatment once per day, for 
four non-consecutive days. The subjects were removed from their home cage, injected with 




separate, covered ‘holding cage’. Twenty minutes post-injection (when the drug, if 
administered, had taken effect) the subject was removed from their ‘holding cage’ and placed 
in the appropriate testing apparatus (see ‘3.3 Behavioural Testing’ section below). Following 
testing, subjects were returned to their home cages except in cases of continuing acute drug 
intoxication (e.g., excessive hyperactivity and hypersensitivity). In these cases they were 
instead returned to their own ‘holding cage’ for up to an hour (to allow for the acute effects 
of the drug to diminish) before then being returned to their home cage. 
3.3 Behavioural Testing 
Behavioural testing occurred 20 minutes following drug treatment (one test per day, 
with each testing day separated by a ‘rest’ day). All subjects were tested using four 
behavioural testing paradigms: an open field (OF), an elevated plus maze (EPM), a light/dark 
box (LD), and a novel object recognition (NOR) test. For each subject, tests were completed 
over seven days, with only one test being performed each day, and each testing day followed 
by a ‘rest’ day. The sequence in which the subjects performed the four different tests was 
counterbalanced based on their cage allocation. All tests were performed in one of two 
experimental rooms under low-light conditions. 
Immediately following each individual subject’s test, the testing apparatus was 
thoroughly cleaned with a 20% Powerquat blue solution to attenuate confounding odour cues 
from previous trials. Further to this, on the days when both males and females were tested in 
the same apparatus, males were always tested first. This was because it has been suggested 
that males may be particularly sensitive to odour cues left behind by females even after 
thorough cleaning (Hughes, 2007).  
All tests were observed via a small CCTV camera suspended over the apparatus. This 




in the room (i.e., so they weren’t standing over the apparatus) and reduced the likelihood of 
their presence affecting the subjects’ behaviour.  
3.3.1 Open Field – Apparatus. The open field consisted of a 600x600mm square 
wooden arena 250mm high. The interior walls and floor of the apparatus were painted black, 
except for white intersecting lines dividing the floor into 16 equal squares (creating a 4x4 
grid pattern). Each square in the grid was numbered 1 to 16. 
3.3.2 Open field – Procedure. At the beginning of the procedure the rat was placed 
into the center of the open field apparatus and 6 seconds later recording began. A behavioural 
sampling procedure was used whereby every 3 seconds (signalled by a small tone generator 
produced by the Smartphone app ‘Encore’, and delivered through an earpiece) the 
experimenter recorded two pieces of data on an OF record sheet (see Appendix B): 1) the 
subjects’ location in the apparatus (as measured by which grid square the majority of the 
animal’s body was occupying), and 2) what behaviour the subject was engaging in; either 
walking (W), rearing (R), freezing (F), or grooming (G). This continued for 5 minutes (100 
observations).  
High frequencies of walking, rearing, and center occupancy (frequency of the subject 
noted in one of the four center squares) are regarded as indices of low anxiety, whereas high 
frequencies of freezing, grooming, and corner occupancy (frequency of the subject noted in 
one of the four corners) are thought to indicate high anxiety (Prut & Belsung, 2003). 
Ambulation (distance travelled, a measure of activity) was later estimated by counting the 
number of transitions between 3-second observations (i.e., the number of times the subject 





At the end of the trial, the number of faecal boluses left in the apparatus (‘defecation’) 
was counted and recorded as a measure of emotionality (more boluses represent greater 
emotionality) (Palanza, 2001). 
3.3.3 Elevated plus maze – Apparatus. The elevated plus maze stood 1 meter off the 
ground and consisted of four 500mm-long x 100-wide arms extending at 90° to each other 
from a central platform (150mm x 150mm). Two opposing arms had 245mm-high wooden 
walls that were painted black (the ‘closed’ arms) and the other two arms had walls instead 
constructed of clear Perspex (the ‘open’ arms). While typically an EPM has a distinct lack of 
walls on its ‘open’ arms (to create an aversive situation for the subjects to experience or 
avoid), the transparent arms on this apparatus prevent a startled rat from leaping off the 
‘open’ arms and do not appear to reduce its aversiveness (Martinez, Cardenas, Lamprea, & 
Morato, 2002).  
3.3.4 Elevated plus maze – Procedure. At the beginning of the test the subject was 
placed in the center platform of the maze, facing one of the open arms. Recording began 3 
seconds later in a similar manner to the OF testing described above. Using an EPM record 
sheet (see Appendix C) the experimenter recorded the number of entries (all four feet) into 
each arm, and every 3 seconds noted whether the subject was occupying one of the open arms 
(O), one of the closed arms (C), or the center platform (X). It was then possible to calculate 
the subject’s percentage of entries into and percentage of time spent in the open arms. These 
measures are regarded as evidence of the subject’s willingness to enter the anxiety-invoking 
open areas of the EPM (Pellow, Chopin, File, & Briley, 1985). The number of entries into the 
closed arms was also noted as this represents a measure of general activity that is not 
confounded by anxiety (Cruz, Frei, & Graeff, 1994). 
3.3.5 Light/dark box – Apparatus. The light/dark box consisted of a 600 x 200 x 




compartment (light side) was painted white and had a clear Perspex lid to allow light to enter. 
The right compartment (dark side) was painted black and had a hinged lid to create total 
darkness when closed. There was a 100 x 100mm opening in the bottom of the wall dividing 
the two sides that could be opened or closed by means of a vertical guillotine slide. 
3.3.6 Light/dark box – Procedure. At the beginning of the trial the subject was 
placed inside the dark compartment with both the lid and slider closed. After 15 seconds the 
slider was opened, allowing the subject free access to both compartments. Using the LD box 
record sheet (see Appendix D) the experimenter recorded the latency (in seconds) for the 
subject to make their first full emergence (all four feet) into the light compartment, and the 
frequency of partial emergences (at least one foot) before their first full emergence. 
Beginning from the time the slider was opened, the experimenter also recorded which 
compartment (L or D) the subject was occupying every 3 seconds for 5 minutes (100 
observations). 
Higher frequencies of entering the light side, greater percentage of time spent in the 
light side, and shorter first emergence latencies are all considered indices of lower anxiety 
(Bourin & Hascoet, 2003). The frequency of partial emergences (before the first full 
emergence) has been suggested to represent a degree of risk assessment in adult rats (Arrant, 
Schramm-Sapyta, & Kuhn, 2013).  
3.3.7 Novel object recognition – Apparatus. The NOR test was conducted in the 
same apparatus as the OF. The ‘familiar’ objects used were two weighted 300ml drink cans. 
The cans were reflective gold in colour, 115mm-high and 60mm in diameter. The ‘novel’ 
object was a cream-coloured stop clock, 115mm x 115mm x 45mm-deep.  
3.3.8 Novel object recognition – Procedure. The NOR test comprised two 
acquisition trials and one retention trial. The subject received drug treatment only before the 




OF apparatus. As such, the subjects’ 5 minute exposures to the apparatus during their OF 
tests (which were always scheduled to occur before their NOR tests) were considered to 
account for their first acquisition trial for the NOR test. The second acquisition trial, designed 
to habituate the subjects to the ‘familiar’ objects, occurred two days later. For this trial the 
two cans were placed in opposite corners of the OF and the subject was entered into the 
apparatus. For 10 minutes the subject was free to move about the apparatus and investigate 
the objects. The subject was then removed from the OF and treated with I.P. mephedrone or 
saline (see ‘3.2 Mephedrone Treatment’). Twenty minutes following their treatment the 
subjects performed the retention trial. One of the two cans (‘familiar’ objects) was removed 
from the OF and replaced with the stop clock (‘novel’ object). The corners containing the 
novel and familiar objects were alternated between subjects to account for any positional or 
lighting preferences in the room. The subject was then placed into the centre of the OF and 
for 5 minutes, every 3 seconds the experimenter recorded on the NOR record sheet (see 
Appendix E) if the subject was in physical contact with, or proximity to the novel or familiar 
objects. ‘Proximity’ was classified as oriented towards and within 2cm of one of the objects. 
From this data a NOR discrimination index was calculated providing a single figure between 
-1 and 1. An index score of greater than zero indicates a preference for the novel object 
relative to the familiar object, whereas an index score of less than zero represents the 
opposite (Hughes, Hancock, & Thompson, 2015; Sutcliffe, Marshall, & Neill, 2007). The 








3.4 Novel object recognition – Test of preference  
A small, independent experiment was performed with 20 adult PVG/c hooded rats (10 
male and 10 female) to determine if there was an inherent preference for one object over the 
other (i.e., a can or a stop clock), irrespective of their novelty values. Similar to the procedure 
described above, one of each of the objects was placed into opposite corners of the open field 
and each subject was allowed five minutes to freely move about the apparatus. Exploration of 
each object was recorded in the same manner as in the NOR retention trial, and the 
mean±SEM total exploration of the can and the clock were found to be 10.25±1.33 and 
9.15±1.25 respectively. This difference was not statistically significant [F(1,36) = 0.46, 
p>0.1], indicating that the subjects did not prefer either the can or the clock more than the 
other when both were equally novel. Female subjects were found to explore both objects 
more than males [females=12.55±1.25, males=6.85±0.97, F(1,36) = 12.40, p<0.01].   
3.5 Non-Behavioural Measures 
 In addition to the behavioural measures each subject’s weight and temperature were 
also recorded. Weight, in grams, for each subject was measured using standard laboratory 
scales on each of the four testing days (necessary to calculate the appropriate volume of 
solution to inject). The weight on the first day was subtracted from the weight on the last day 
to give a figure representing the change in weight for that subject over the seven days of 
testing. It was then possible to compare weight gain (or loss) over this time between the 
different experimental groups.  
 The subjects’ temperature was also recorded, using a Braun IRT 4020 ThermoScan 
aural thermometer. Temperature recordings were taken on each testing day for all subjects. 
The first recording was taken at time of drug (or saline) administration, and the second was 
taken immediately following behavioural testing (i.e., 25 minutes following drug 




representing the change in temperature, and this ‘difference score’ was averaged for each 
subject over the four testing days. The final figure then was an average temperature change 
(in degrees Celsius) for each subject, and allowed for comparisons to be made between 


























 Unless otherwise stated, all measures were statistically analysed using separate 5 
(drug) × 2 (sex) ANOVAs, and Fisher PLSD post hoc comparisons (p<0.05). Where 
appropriate, ANCOVAs were also utilised in order to test the significance of a given result 
after accounting for a potentially confounding co-variable. In some specific cases, trend 
analyses were performed when visual inspection revealed potential patterns in the data. The 
experimental design, with 5 increasing doses of mephedrone, meant that the use of these tests 
in this manner was reasonable given the exploratory nature of the experiment (Cohen, 2008). 
All analyses were performed using Statistica 12 software by StatSoft©. 
 A number of subjects were excluded from the final analyses for various reasons: 
subject 95 (female, 60mg/kg) was excluded from the open field results due to ‘seizure-like’ 
activity during the testing. Subject 41 (male, 60mg/kg) was excluded from the elevated plus 
maze results due to an error in drug administration. Subject 26 (male, 20mg/kg) was excluded 
from the novel object recognition test results due to missing the required habituation trial. 
Subject 91 (female, 60mg/kg) experienced an adverse reaction to the drug treatment and was 
euthanized before participating in the novel object recognition test, and so did not contribute 
to the data pool for that particular test. 
4.1 Open Field Results 
 The effects of increasing mephedrone doses on the behavioural measures examined in 
the open field are displayed in Figure 1. As can be seen: rearing and grooming behaviours, as 
well as defecation, decreased with higher doses of mephedrone; freezing behaviours and 
corner occupancy increased with higher doses; and ambulation, walking, and center 





It was posited that the center and corner occupancy measures might potentially be 
confounded by hyperactivity (e.g., a subject running quickly around the edges of the open 
field has more opportunity to be recorded as having occupied a corner square on any given 
observation). To assess this, these measures were also analysed used ANCOVA, with 
ambulation as a co-variable. The effects of mephedrone on both center and corner occupancy 





Figure 1. Mean ± S.E.M. frequencies for (A) ambulation, (B) walking, (C), rearing, (D) freezing, (E) 
grooming, (F) center occupancy, (G), corner occupancy, and (H) defecation recorded in the open field 
following treatment with four doses of mephedrone. Data represents results for both male and female 
rats combined. 
*Significantly different from control group (p < 0.05). 



















Mephedrone Dose (mg/kg/day) 



























































Mephedrone Dose (mg/kg/day) 














Mephedrone Dose (mg/kg/day) 
D. Freezing 
* 













Mephedrone Dose (mg/kg/day) 
E. Grooming 
*abc 




































Of the 8 behavioural measures examined in the open field, 3 were found to have 
significant drug × sex interactions. The results for ambulation [F(4,89) = 2.52, p <0.05], 
center occupancy [F(4,89) = 3.62, p <0.01], and corner occupancy, [F(4,89) = 3.60, p <0.01] 
are displayed in Figure 2.  
 
Figure 2. Mean ± S.E.M. frequencies for Sex × Drug interactions for (A) ambulation, (B) center 
occupancy, and (C), corner occupancy in the open field following treatment with four doses of 
mephedrone.  
*Significantly different from control group for that sex (p < 0.05). 
# Signifies a significant difference between males and females for that dose (p < 0.05).  
 
 For ambulation and center occupancy, male subjects displayed first an increase, then a 
decrease in each behaviour as mephedrone dose increased (peaking at 20mg/kg), whereas 
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occupancy. For corner occupancy, males displayed a decrease followed by an increase, 
whereas females displayed a consistent increase. Upon visual inspection of these findings it 
appeared that males and females responded in two distinct patterns on each measure. To test 
this, a number of trend analyses were performed. It was found that the pattern of responding 
for males followed significant quadratic trends for ambulation [F(1,89) = 7.43, p<0.001], 
center occupancy [F(1,89) = 6.32, p<0.001], and corner occupancy [F(1,89) = 9.88, p<0.001] 
measures. For females, a linear pattern of responding was significant for the corner 
occupancy measure [F(1,84) = 4.86, p<0.01], though not for ambulation or center occupancy 
[F(1,84) = 1.79, p=0.14; and F(1,84) = 1.56, p=0.18 respectively]. 
4.2 Light/Dark Box Results 
 Figure 3 shows the effects of increasing doses of mephedrone on subjects’ behaviour 
in the light/dark box. As can be seen, mephedrone decreased the percent observations in the 
light side, as well as decreasing the number of entries into the light side up to a dose of 
20mg/kg. For doses higher than 20mg/kg the direction of this effect was reversed, with 
observations and entries increasing. In contrast, the first emergence latency increased 
dramatically in doses up to 20mg/kg, before decreasing in doses above that point. 1mg/kg 
was the only dose that had a significant impact on the number of prior emergences into the 







Figure 3. Mean ± S.E.M. results for (A) percent observations in the light side, (B) number of entries 
into the light side, (C), first emergence latency, and (D) number of prior, partial emergences into the 
light side recorded in the light/dark box following treatment with four doses of mephedrone. Data 
represents results for both male and female rats combined. 
*Significantly different from control group (p < 0.05). 
a,b,cGroups with superscripts in common are significantly different (p < 0.05).  
  
Following visual inspection of the male and female data for these measures a number 
of potential patterns were explored using trend analysis. For entries into the light side male 
subjects showed a significant linear trend [(F1,90) = 4.41, p<0.01] with number of entries 
decreasing as mephedrone dose increased, whereas females showed a significant quadratic 
trend [(F1,90) = 6.11, p<0.001], displaying first a decrease, then an increased after 20mg/kg. 
The same patterns were also observed in the percent observations in the light side measure 




























Mephedrone Dose (mg/kg/day) 


















Mephedrone Dose (mg/kg/day) 























Mephedrone Dose (mg/kg/day) 



















Mephedrone Dose (mg/kg/day) 




4.3 Elevated Plus Maze Results 
As can be seen in Figure 4, increasing doses of mephedrone had no significant effect 
on the percent observations in, or percent entries into the open arms of the elevated plus 
maze. The number of entries into the closed arms was significantly decreased at doses of 
20mg/kg and higher. Factoring out entries of closed arms (an activity measure considered 
uncontaminated by anxiety) from percent entries of open arms did not alter the results enough 
to detect a significant effect of drug [F(4,92) = 1.03, p=0.40].  
 
Figure 4. Mean ± S.E.M. results for (A) percent observations in the open arms, (B) percent entries 
into the open arms, and (C), number of entries into the closed arms recorded in the elevated plus maze 
following treatment with four doses of mephedrone. Data represents results for both male and female 
rats combined. 
*Significantly different from control group (p < 0.05). 
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A significant drug × sex interaction was found for the number of entries into the 
closed arms measure [F(4,89) = 5.44, p <0.001]. As can be seen in Figure 5, the number of 
entries appears to be trending down as the mephedrone dose increases, except for the notable 
increases at 40mg/kg for males (but not for females), and at 60mg/kg for females (but not for 
males). 
 
Figure 5. Mean ± S.E.M. frequencies for Sex × Drug interactions for total entries into the closed arms 
of the elevated plus maze.  
*Significantly different from control group for that sex (p < 0.05). 











Dose 0 1 20 40 60
Mean M 7.8 7.9 3.1 7.9 2.22
SEM M 0.55 0.75 1.23 2.19 1.49
Mean F 8.3 8.7 6.6 2 5.7
































4.4 Novel Object Recognition Results 
 The effects of mephedrone on the novel object recognition discrimination index (see 
3.3.8 Novel Object Recognition - Procedure) are displayed in Figure 6. As can be seen, the 
discrimination index is greater than zero for each group, indicating that regardless of 
experimental condition there was a preference for exploring the novel object relative to the 
familiar one. Mephedrone dose failed to produce any significant overall effects [F(4,85) = 
1.59, p=0.18], as did sex [F(1,85) = 1.46, p=0.23], though the sex × drug interaction was 
significant, [F(4,85) = 4.72, p<0.01] with males trending higher on the discrimination index 
at 60mg/kg, whereas females showed a decrease. 
 
Figure 6. Mean ± S.E.M. results for male and female scores on the discrimination index in the novel 
object recognition test.  
*Significantly different from control group for that sex (p < 0.05). 






Dose 0 1 20 40 60
Mean M 0.28 0.53 0.25 0.32 0.83
SEM M 0.06 0.05 0.14 0.21 0.08
Mean F 0.35 0.08 0.33 0.7 0.24

































4.5 Sex Differences 
 For each measure recorded in the four behavioural tests overall sex differences were 
also examined, averaging scores across mephedrone (and saline) doses. The descriptive 
statistics and ANOVA results for males and females on each measure are summarised in 
Table 2. Female subjects travelled significantly further distances (ambulation) than males, 
and spent more time in the corner squares and less time in the center squares of the open 
field. They also made more entries into the light side of the light/dark box, and were observed 
spending more time in the light side compared to males. For most of the non-significant 
measures the frequencies of observed behaviours were generally higher for females than for 
males, such as walking and rearing in the open field, and entries into open and closed arms in 
the elevated plus maze. 
Table 2 
Means, S.E.Ms, and ANOVA results for main effects of Sex on all measures.  
 Sex of Rats  
Measure Male Female F(1,56) 
Open Field    
Ambulation 68.02(±2.59) 76.29(±2.06) 8.21** 
Walking 71.92(±2.86) 73.27(±3.05) 0.46 
Rearing 10.78(±2.33) 12.67(±2.55) 1.87 
Freezing 17.18(±1.79) 13.49(±2.18) 1.70 
Grooming 0.12(±0.06) 0.20(±0.07) 0.96 
Centre Occupancy 18.46(±2.20) 11.43(±1.70) 8.08** 
Corner Occupancy 34.94(±2.78) 43.73(±2.51) 8.97** 
Defecation 0.70(±0.19) 0.37(±0.16) 2.11 
Light/Dark Box    
1st Emergence Latency (Seconds) 164.72 (±19.84) 135.76 (±19.44) 3.03 
Entries into Light Side 2.24 (±0.38) 4.24 (±0.82) 6.52* 
Observations in Light Side 10.92(±1.96) 19.72 (±3.01) 10.23** 
Partial Entries into Light Side 0.38 (±0.11) 0.38 (±0.12) 0.00 
Elevated Plus Maze    
% Entries in Open Arms 44% (±4%) 53% (±3%) 2.79 
% Observations in Open Arms 45% (±5%) 54% (±4%) 2.03 
Entries into Closed Arms 5.86 (±0.34) 6.26 (±0.52) 0.42 
Novel Object Recognition    
Discrimination Index 0.44(±0.06) 0.33(±0.07) 1.46 






4.6 Non-Behavioural Measures 
 The average difference in the subjects’ weight between the first and last testing days 
(PND100 to PND107) is displayed for males and females separately in Figure 7. The results 
indicate that male subjects receiving doses of 20mg/kg or less of mephedrone gained between 
6 and 10 grams over the testing cycle, whereas those receiving high doses of mephedrone 
gained significantly less weight (and in the case of the high dose group, lost weight). Female 
subjects appeared to gain between 0 and 4 grams, and there was no significant increase or 
decrease from control for any dose. This was a significant drug × sex interaction, F(4,89) = 
7.05, p<0.001.    
 
Figure 7. Mean ± S.E.M. results for weight difference (in grams) over the 7 days of testing for both 
male and female subjects in each experimental group.  
*Significantly different from control group for that sex (p < 0.05). 








Dose 0 1 20 40 60
Mean M 8.3 9.9 6.5 1.3 -1.5
SEM M 1.87 1.84 1.33 1.58 2.19
Mean F 0.7 1.9 -0.5 3.2 2.33




































 Temperature data were recorded pre- and post-drug administration, and averaged 
across testing. Figure 8 displays the average temperature increase for male and female 
subjects 20 minutes after injection. As can be seen, both sexes experienced an increase in 
body temperature at all doses; however, female subjects showed an increasing difference as 
the mephedrone dose increased, whereas the increase for males appeared to peak at 20mg/kg. 
 
Figure 8. Mean ± S.E.M. results for average temperature difference (in degrees Celsius), 20 minutes 
following treatment with mephedrone for both male and female subjects.  
*Significantly different from control group for that sex (p < 0.05). 











Dose 0 1 20 40 60
Mean M -0.14 0.37 0.67 0.74 0.83
SEM M 0.09 0.1 0.12 0.1 0.16
Mean F -0.13 0.06 0.55 1.3 1.73





































Experiment 1 examined the anxiogenic properties of mephedrone over a range of 
doses. Both male and female subjects were administered 1, 20, 40, or 60 mg/kg of 
mephedrone (or saline) before being tested in an open field, light/dark box, elevated plus 
maze, and novel object recognition behavioural paradigm. The results of these tests supported 
Hypothesis 1 that mephedrone would be anxiogenic, producing more anxiety-related 
behaviours relative to the saline control group. Hypothesis 2 concerned the dose-response 
relationship between mephedrone and anxiety-like behaviours. It was predicted that this 
relationship would produce an inverted ‘U’ shaped curve (an initial increase in observable 
anxiety-like behaviours, followed by a decrease). The results of testing partially supported 
this hypothesis, though there were some interesting sex differences in the dose-response 
trends for several tests.  
5.1 Open Field Findings 
   Mephedrone produced an overall increase in corner occupancy in the open field; as 
well as a decrease in rearing, grooming, and center occupancy. Taken together, these results 
are indicative of heightened anxiety, support Hypothesis 1, and are consistent with previous 
studies examining anxiogenic drugs (e.g., Aitchison & Hughes, 2006; Pometlova et al., 2012; 
Quinteros-Munoz et al., 2010; Thompson, 2012). While there was no statistically significant 
change in freezing behaviours, the data does appear to be trending upwards with high doses 
of mephedrone, which would similarly suggest increased anxiety. 
The ambulation and walking measures also displayed significant increases following 
treatment with mephedrone. While higher scores on these two measures do not typically 
indicate increased anxiety, these results are consistent with the increase in locomotor activity 




Gatch et al., 2015; Sahakian, Robbins, Morgan, & Iverson, 1975). This increased locomotor 
activity may also explain the lack of significant findings for the freezing behaviours measure. 
The results for defecation, a measure thought to represent levels of emotionality 
(Anderson & Hughes, 2008), show a significant decrease following treatment with 
mephedrone, which runs contrary to the hypothesis and the other results. This unexpected 
finding however, can potentially be explained by the methodology of this particular 
experiment: because subjects were tested 20 minutes following drug administration (in order 
to allow for the drug to take full effect) it is entirely plausible that these subjects, made 
anxious by the oncoming drug effects, defecated in their temporary holding cages prior to 
being placed in the testing apparatus. Conversely, the control subjects, experiencing no 
anxiogenic effects of drug treatment and comfortable in their dark holding cages, would 
instead defecate only after being introduced to the anxiety-inducing testing apparatus. Given 
that the number of faecal boluses was counted only in the testing apparatus and not the 
holding cages, it may be that this measure is not valid with the present methodology. 
 When looking at the results across the dose range tested; ambulation, walking, and 
corner occupancy measures all show initial increases, peaking at 20mg/kg, before decreasing. 
The corner occupancy measure appears to display the opposite (a decrease, followed by an 
increase) though as lower levels of this measure represents more anxiety we can interpret this 
result to be the same as the others. Taken together these results would appear to support 
Hypothesis 2 (an inverted ‘U’ shaped dose-response curve), however, when the results for 
males and females are examined separately an interesting phenomenon can be observed. The 
predicted ‘U’ shaped curves for ambulation, center occupancy, and corner occupancy (later 
found to be significant quadratic trends) are found for male subjects only. Female subjects, 
conversely, appear to display a more linear dose-response relationship with higher doses of 




replicated (albeit inversely) in both the center and corner occupancy measures adds validity 
to the detected effect, and suggests it is not simply an artefact of the data. The effect has not 
been found in previous studies, which suggests that either it is unique to mephedrone, or 
more likely, it is a consequence of the research literature’s traditional use of male-only 
experimental designs (Hughes, 2007; Kokras & Dalla, 2014).  
 The inverted ‘U’ shaped curve found in previous research has been suggested to be a 
result of stereotypy behaviours contaminating the behavioural measures at higher doses 
(Clemens et al., 2006). This explanation is consistent with observations made by the 
experimenter in the current study, wherein subjects on higher doses of the drug were 
observed: tracing the outside walls of the apparatus (‘thigmotaxis’), turning repeatedly in 
tight circles (‘gyration’), and engaging in repetitive head swaying behaviours. If performed 
frequently enough, these behaviours could plausibly confound several of the behavioural 
measures recorded in the open field: for example, one 60mg/kg subject spent the entire 5 
minutes of the test running clockwise around the exterior boundary of the apparatus. This 
animal would then be disproportionately likely to be recorded as having occupied a corner 
square on a given observation, even though doing so was largely an artefact of increased 
thigmotaxis rather than ‘hiding’ in the relative shelter of the corner. Center occupancy would 
be likewise affected, as an animal tracing the boundary of the apparatus would have no 
opportunity to be observed occupying the center squares.  
These notes on stereotypy must be considered when interpreting the results of the 
experiment, though they do not necessarily mean that the initial findings are invalid. 
Increased anxiety may be strongly correlated with increased stereotypy, which would go 
some way to explaining the inverted ‘U’ shaped curve: anxiety increases beyond the peak, 
and accordingly so does stereotypy, potentially resulting in behaviours that erroneously 




or at least overtly responded in a different way, this theory could explain the unexpected sex 
differences found in the dose-response relationships. It may be that higher doses of 
mephedrone produce greater anxiety for both male and female subjects, though after a certain 
point (in this case, 20mg/kg) the two sexes differ in their overtly observable behaviours 
(namely, stereotypy).  
5.2 Light/Dark Box Findings 
 In the light/dark box, mephedrone decreased the percent observations in and number 
of entries into the light side of the apparatus, as well as increasing the first emergence 
latency. As with the open field findings, these results in the light/dark box suggest increased 
anxiety following treatment with mephedrone compared to saline control. These findings 
support Hypothesis 1, and are consistent with results from the drug literature (Bourin & 
Hascoet, 2003). The number of partial emergences made prior to the first full emergence has 
been suggested to be a measure of risk assessment behaviour. Interestingly, in this 
experiment only the 1mg/kg dose produced a significant increase in the number of partial 
emergences, with no differences seen at the higher doses. It is possible that at this lowest 
mephedrone dose the subjects, while not ‘anxious’ per se, could detect that ‘something’ was 
not normal and accordingly adopted a more cautious approach to investigating the (novel) 
light side of the apparatus. While the control subjects had little trouble entering the light side, 
the more anxious (higher dose) subjects appear to have taken a more ‘all or nothing’ 
approach to entering. It may be that at a low dose mephedrone induces a general or vague 
sense of discomfort that translates into increased risk assessment and cautionary behaviours, 
not unlike a mildly intoxicated driver being excessively careful because he understands he 
may be impaired. 
 The dose-response relationship seen in the light/dark box results is similar to that in 




side measures both produced an inverted ‘U’ shape curve indicating an initial increase in 
anxiety-like behaviours followed by a decrease. These findings would appear to support 
Hypothesis 2, although when male and female results are viewed separately another sex 
difference emerges (again similar to the open field results). This time it is the females who 
display an inverted ‘U’ shaped, ‘quadratic’ trend for these two measures, whereas the males 
display a linear trend (higher doses translates to more anxiety). A surprising result, this 
finding may best be explained by the same theory put forward to explain the open field 
differences: that higher doses of mephedrone cause more stereotypy behaviours, and that 
these stereotypy behaviours are expressed differently for males and females. If stereotypy in 
males is expressed via relatively more non-ambulatory behaviours (such as head swaying) 
than females (who express stereotypy via more ambulatory behaviours such as thigmotaxis), 
then such stereotypy would result in different findings in the open field (where more 
locomotor activity generally increases scores, and increased scores on several measures 
represents more anxiety) than the light/dark box (where decreased locomotor scores indicate 
higher anxiety). For example, a male subject that sits still and engages in stereotypic head 
swaying for the entire 5 minutes of each test would likely score low on anxiety across the 
open field measures (little movement means less chance of being observed performing 
anxiety-like behaviours), whereas the same subject would score high on anxiety in the 
light/dark box (with few, if any, entries into the light side). Females, on the other hand, are 
already known to be more ambulatory than males (Archer, 1975; Johnston & File, 1991), and 
if their stereotypy behaviours reflect this then it follows they would appear to score lower on 
anxiety in the open field, and higher in the light/dark box compared to males at high doses. 
5.3 Elevated Plus Maze Findings 
 Mephedrone did not significantly affect the percentage entries into the open arms, or 




as previous studies conducted with similar drugs would lead us to expect mephedrone to 
decrease the entries into and time spent in the open arms respectively (Cruz et al., 1994; 
Martinez et al., 2002; Pellow et al., 1985; Silva & Brandao, 2000). The lack of significant 
findings here could be explained by one of the following explanations. (A): mephedrone does 
not affect subjects’ preferences for either the open or closed arms in an elevated plus maze, 
and the current results accurately reflect this. This explanation seems unlikely given the 
results of the open field and light/dark box, which both suggest mephedrone produces 
anxiogenic effects, and more anxiety should translate to a preference for the closed arms in 
the elevated plus maze. (B): mephedrone does produce an effect on these measures, but the 
methodology of the current study is somehow flawed and so failed to detect it. This 
explanation also seems insufficient, as the current methodology used is an exact replication 
of that from several previous studies where significant effects were detected (Hughes, 
Hancock, Henwood, & Rapley, 2014; Hughes et al., 2015). (C): Another factor, unforeseen 
but unique to this study, has impacted on the ability of the test to detect an effect. This 
explanation seems plausible in light of the stereotypy observations already discussed for the 
open field and light/dark box. It may be that the elevated plus maze is more sensitive to the 
confounding effects of stereotypy than these other tests, and this is again consistent with 
observations made by the experimenter. Notably, many high-dose subjects, when placed in 
the apparatus would run to the end of the first arm they faced, and then pause, swaying their 
heads back and forth for the entirety of the test. If stereotypy is positively correlated with 
anxiety, and stereotypy also confounds observable anxiety measures in the elevated plus 
maze, then the lack of significant effects detected in the current study could strangely enough 
be plausible evidence of an anxiety response. 
 The number of entries into the closed arms of the elevated plus maze was included as 




more, produced a significant reduction of entries into the closed arms, indicating that at these 
higher doses the subjects were less active (as measured by the test). This is not inconsistent 
with the above theory, as the increase in stereotypy behaviours would correlate with a 
decrease in ‘detectable’ locomotion (in this case, arm entries) if the animals are instead (A): 
not moving while they sway their heads back and forth; or (B): running in tight circles 
(‘turning on the spot’).  
 Taken together, the results from the elevated plus maze are somewhat inconclusive, 
though they could plausibly support Hypothesis 1 that mephedrone produces an anxiogenic 
effect, if stereotypy is taken into consideration. There is no evidence of a dose-response 
relationship to support Hypothesis 2. 
5.4 Novel Object Recognition Findings 
 While not strictly a measure of anxiety, the novel object recognition task was added to 
examine the effects of mephedrone on recognition memory. The results showed that all 
subjects displayed a preference for the novel object relative to the familiar one, regardless of 
experimental condition, suggesting that mephedrone does not affect recognition memory. It 
should be noted however, that once again stereotypy might potentially have confounded some 
of the results, the experimenter noted that it was difficult at times to make a subjective 
determination as to whether an animal was ‘actively exploring’ an object (close to and 
oriented towards it) or simply ‘head swaying’ in its vicinity. With no quantitative way to 
factor out stereotypy effects, the results must be interpreted carefully, with this possibility in 
mind. 
5.5 Sex Differences 
 In addition to those already discussed, there were a number of overall sex differences 
noted across the behavioural tests. Females displayed significantly more ambulation and 




indicative of females being generally more anxious than males, however; in the light/dark 
box females made more entries into the light side and were also observed more frequently in 
the light side, indicative of less anxiety than males. There were no significant sex differences 
found in the elevated plus maze or novel object recognition tests. These seemingly 
contradictory findings are consistent with previous research that has failed to conclusively 
find one sex to be more anxious than the other (Johnston & File, 1991). Rather than reflecting 
anxiety, specifically, the competing results from the open field and light/dark box (females 
are more anxious, and less anxious respectively compared to males) may be a product of 
locomotor activity. Females are well known for being more ambulatory than males (Archer, 
1975), and the nature of the test measures is such that greater ambulation in the open field 
lends itself to more anxiety-like responses, whereas in the light/dark box the opposite is true 
(greater ambulation translates to less anxiety-like scores). 
5.6 Non-Behavioural Measures 
 Weight gain over the seven days of testing, as well as average temperature increase 
post-injection were also recorded in this experiment. Mephedrone did not appear to affect the 
weight gain of female subjects, which put on between 0g and 3g consistently across the 
various doses. Male subjects however, were significantly affected by treatment with 
mephedrone, with 40mg/kg subjects only gaining between 1g and 2g over the week 
(compared to 8g or 9g for saline control subjects), and some 60mg/kg animals actually lost 
weight. It is unclear from the current study why mephedrone would produce this effect, 
though it could be the result of: loss of appetite, increased locomotor activity, increased 
metabolic rate, or a combination of these and other factors. 
 The aural temperature of the subjects was recorded at the time of injection, and again 
25 minutes later immediately following behavioural testing. The difference in these 




mephedrone on the subjects’ temperature. The results showed that mephedrone significantly 
increased the temperature of the subjects at all doses, though the effect was different for male 
and females. Male subjects’ temperatures were raised by over half a degree at 20mg/kg, 
though this increase levelled off and was similar for the higher doses as well. Females’ 
temperatures showed a similar increase at 20mg/kg, though this increase was more linear, 
continuing to increase at higher doses until being over 1.5 degrees at 60mg/kg.  
5.7 Adverse Effects 
 There were a number of adverse effects of mephedrone on some subjects recorded by 
the experimenter. These effects occurred almost entirely at doses in excess of 20mg/kg, and 
primarily in female subjects. Most notably, 3 high-dose female subjects experienced seizure-
like activity during behavioural testing. The animals would suddenly freeze, as if startled, and 
then jerk violently for upwards of 10-20 seconds. Afterwards they appeared exhausted and 
panted motionlessly for a time. One of these animals was later euthanized when it failed to 
respond to the interventions of the animal technicians. The other two made full recoveries 
after rest and fluids. A general pathology report on the deceased animal did not return any 
remarkable findings, and it was posited by the animal technicians and the researcher that 
hyperthermia was likely the proximate cause.  
 A number of animals were found to have wet fur under their chins following 
behavioural testing (see Figure F1 in Appendix F). After a quick search of the literature this 
was identified as a condition called ‘heat prostration’. Usually a result of rats being shipped 
in a high ambient temperature, the condition causes increased respiration and excessive 
salivation resulting in wet mouths, muzzles, and paws. The condition is thought to be a 
response by the rat of applying saliva to the fur in an attempt to cool down (Sharp & La 




discussed earlier, is further evidence of the very real risk of hyperthermia when using high 
doses of mephedrone (particularly for females). 
 Four animals developed abscess-like wounds at the I.P. injection sites. While 
alarming and gruesome to observe (see figure F2 in Appendix F), the sores did not seem to 
cause the subjects undue discomfort (i.e., they did not respond when the sores were touched). 
The sores were monitored, and healed themselves over a period of 1-3 weeks. The subjects 
concerned were males and females, from either the 40mg/kg or 60mg/kg experimental 
groups. It is not clear why some animals developed the sores while the majority of others did 
not. 
 Other less extreme, though no less interesting effects were also noted at high doses of 
mephedrone use. Subjects treated with over 20mg/kg frequently exhibited agitation, 
increased locomotor activity, hypersensitivity to touch and to sound, and exaggerated startle 
reflex. The high dose rats were often difficult to handle, sometimes requiring the researcher 
to gently wrap them in a tea towel in order to pick them up. Many of these symptoms are 
consistent with the literature reporting the effects of mephedrone use in humans (see Table 1, 
page 6). 
5.8 Limitations and Future Research 
 On examination and discussion of the results from Experiment 1, the primary 
methodological limitation is almost certainly the lack of any quantitative means of assessing 
(and therefore factoring out) stereotypy behaviours. While not necessarily invalidating the 
current findings, increased stereotypy is clearly a significant effect of mephedrone 
(particularly at high doses) and a large factor that was not controlled for in the current study. 
A number of the conclusions drawn rely on theory and conjecture that can be logically 
inferred from the results, though not conclusively shown. It is therefore important that 




own sake, but also to be able to factor them out of the anxiety-related measures, or to at least 
make more informed statements about the potential for confounded results. 
 There is a large ‘jump’ in the mephedrone doses used in this experiment, from 
1mg/kg to 20mg/kg. This was necessary to cover the full range of doses examined in only 5 
different experimental groups, though conceivably there is information ‘lost’ in the gap 
between 1 and 20 mg/kg. Given that the pattern of responding is the primary feature of a 
dose-response relationship, it will be important to examine an intermediate dose or doses in a 
future study.  
 As discussed earlier, the defecation measure in the open field may not be a valid 
measure of emotionality in the current study due to the time spent in the holding cage 
(between injection and behavioural testing), where changes in this behaviour went 
unrecorded. If a future experiment required the same methodology of drug administration, 
counting faecal boluses both in the testing apparatus and in the holding cage could mitigate 
this limitation.  
 The novel object recognition task may have been confounded by stereotypy 
behaviours that appear similar to exploratory ones (e.g., head swaying in proximity to an 
object can be hard to distinguish from sniffing or ‘exploring’ the object). One way to 
potentially remedy this in a more specific, though less sensitive observation, might be to 
record only contact with an object as indicative of ‘exploration’, rather than contact plus 
proximity. 
5.9 Conclusion 
 The results from Experiment 1 appear to support the first hypothesis that mephedrone 
would produce anxiety-like behaviours similar to other stimulant drugs. There may be partial 
support for the second hypothesis, that mephedrone would produce an inverted ‘U’ shaped 




of interesting drug × sex interactions, most notably that on a number of measures male rats 
display a quadratic (inverted ‘U’ shape) dose-response relationship, whereas females display 
a linear one. Even more unexpectedly, this pattern of responding for males and females is 
then reversed on some other measures. A theory was proposed to explain these findings, 
which posits that (A): high doses of mephedrone result in stereotypy behaviours, and (B): 
stereotypy behaviours are expressed differently for male and female rats. More research is 
needed to examine the effects of stereotypy, and potentially add some validity to the current 





















6.0 Experiment 2 – Stereotypy 
 6.1 Stereotypy Overview 
 The term ‘stereotypy’ refers to a repetitive or ritualistic set of behaviours that appear 
compulsive and without any apparent purpose (Stereotyped behaviour induced by 
amphetamine, 1972). They are observed throughout the animal kingdom from invertebrates, 
to birds, to mammals, including humans (Ridley, 1994). At the lower levels of phylogeny 
these ‘fixed action patterns’ are thought to be a response to specific events in the 
environment, and once triggered, are performed until another event (often the outcome of the 
fixed action pattern) changes the animals’ behaviour, which in many cases is to another fixed 
action pattern. Some moths, for example, will instantly fold their wings and drop to the 
ground (fixed action pattern) in response to certain ultrasonic signals produced by bats 
(trigger event) (Roeder, 1975). Other examples include courtship displays, hunting, nest 
building, and attack or escape movements (NC State University, 2006). In humans and other 
higher mammalian species these fixed action patterns are often considered ‘reflex 
behaviours’, though our behavioural repertoires generally also extend to flexible, self-
initiated, and voluntary behaviours as well. The loss of these latter abilities is an important 
feature of various psychopathologies, such as autism spectrum disorders, intellectual 
disabilities, tardive dyskinesea, Tourette’s syndrome, fronto-temporal dementia, obsessive 
compulsive disorder, and schizophrenia (Ridley, 1994). Stereotypy behaviours can range 
from simple to complex bodily movements (motor stereotypies) but can also include 
“repetitive, inflexible patterns of attention, emotion, planning and cognition typifying some 
clinical disorders in humans” (Canales & Grabiel, 2000, p. 377). 
6.2 Induced Stereotypies 
 Stereotypy behaviours have been observed and can be induced in animals in a number 




6.2.1 Confinement stereotypy. Also called ‘cage stereotypy’, these behaviours can 
occur when mammals are confined in small cages or enclosures, such as in zoos or in 
laboratory settings. The repetitive behaviours generally involve abnormal locomotion (e.g., 
pacing up and down one side of the enclosure) or ‘bar mouthing’ (the animal opens its mouth 
wide on the bars of their cage, and makes ‘sham’ biting movements). Confinement 
stereotypies are thought to result from the environment impairing the animals’ ability to 
perform species-specific behaviours (such as foraging, hunting, or interacting with other 
animals), and as such are easily broken by providing a bigger, more stimulating enclosure 
with access to the above opportunities (Ridley, 1994). 
6.2.2 Deprivation stereotypy. These behaviours are observed in animals that have 
been reared in isolation, and usually consist of repetitive movements of body parts (such as 
rocking, head banging, or sucking fingers or thumbs). The behaviours can often be socially 
inappropriate (e.g., aggressive, or sexual in nature), and self-harming (Ridley, 1994). It has 
been suggested that unlike confinement stereotypy, which is a result of the environment, 
deprivation stereotypy is due to the lack of interaction with the environment during a critical 
developmental period. In humans, this may plausibly explain the high degree of motor 
stereotypies observed in severely autistic individuals, where their neurodevelopmental 
condition has impaired their ability to interact with their environment during a critical period 
in infancy (Ridley, 1994). Studies using rats have shown that environmental conditions 
during infancy can have a permanent effect on brain biochemistry, and accordingly, 
deprivation stereotypies are extremely difficult to disrupt (Ridley, 1994; Sahakian et al., 
1975). 
6.2.3 Drug-induced stereotypy. Stimulant drugs like amphetamine and cocaine have 
been consistently shown to produce stereotypy behaviours in laboratory animals. These drugs 




hyperactive behaviours that are without apparent purpose (Stereotyped behaviour induced by 
amphetamine, 1972). Common examples of stereotyped behaviours followed amphetamine 
treatment include: head swaying/bobbing, limb movements, sniffing, licking, and biting of 
the home cages (Wolgin, 2012). These behaviours are not simply a result of overstimulation, 
as sedative drugs like benzodiazepine are unable to inhibit them, even when administered at 
doses that interfere with the righting reflex (Stereotyped behaviour induced by amphetamine, 
1972). Stereotypy-inducing drugs appear to disrupt the normal, integrated activity of the 
brain, suspending goal-directed behaviours and responses to meaningful environmental 
stimuli (Wolgin, 2012). 
6.3 Experiment 2 Aims and Hypotheses 
 Experiment 2 sought to examine the effects of mephedrone on anxiety-related 
behaviours in hooded rats, as well as quantifying the stereotypy behaviours observed in 
Experiment 1. Using a similar methodology to the earlier experiment, this study looked more 
closely at the ‘active range’ of mephedrone doses identified (and removed the two highest 
doses which produced the most adverse effects). In Experiment 1, males and females differed 
in their dose-response patterns of responding primarily at doses above 20mg/kg. As in the 
current study 20mg/kg was the highest dose, it was hypothesised that mephedrone would 
produce more anxiety-like behaviours as dose increased, and that the dose-response pattern 
would be the same for males and females. 
 Additionally, Experiment 2 included a number of stereotypy measures meant to assess 
behaviours observed in Experiment 1. Based on previous observations and on explanatory 
theories proposed in discussion of the previous results, it was hypothesised that mephedrone 
would induce more stereotypy behaviours as dose increased, and that males and females 







 The subjects used in this study were 32 male and 32 female PVG/c hooded rats bred 
in the Animal Facility of the Department of Psychology at the University of Canterbury, 
Christchurch, New Zealand. Following weaning at PND30 (Postnatal day 30) the subjects 
were housed in 525 x 330 x 230mm-high plastic cages in groups of four same-sexed animals. 
They were kept on a 12-hour light/dark cycle (lights on at 0800 hours) at an ambient 
temperature of 22 ± 2°C (with humidity of 48% ± 10%). All subjects had free access to 
standard laboratory food and drinking water at all times. The care and experimental treatment 
of subjects complied with Parts 5 (Code of Welfare) and 6 (Use of Animals in Research, 
Testing and Teaching) of the New Zealand Animal Welfare Act, 1999 and had been approved 
by the Animal Ethics Committee of the University of Canterbury (See Appendix G). 
7.2 Mephedrone Treatment 
  The subjects were randomly assigned to one of four conditions, with each condition 
containing 8 male and 8 female subjects.  The conditions were: 1mg/kg, 10mg/kg, or 
20mg/kg of mephedrone, and a saline control group. This dose range was selected to 
represent the most active and interesting range found in Experiment 1 (with 10mg/kg added 
to observe any effects between the otherwise large jump from 1mg/kg to 20mg/kg). 40mg/kg 
and 60mg/kg were discontinued in this experiment due to adverse effects observed in 
Experiment 1. The mephedrone used in this study was synthesised on-site in the Department 
of Psychology at the University of Canterbury. The resulting mephedrone 98% salt was 
dissolved daily in isotonic saline to create solutions of the various dosages. These doses were 
then administered to the subjects via intraperitoneal (I.P.) injections in a volume of 1ml/kg.  
At approximately PND100 (adulthood) all subjects were treated once per day, on two 




appropriate solution (with respect to their assigned experimental condition), and then placed 
in their own separate, covered ‘holding cage’. Twenty minutes post-injection (when the drug, 
if administered, had taken effect) the subjects were removed from their ‘holding cage’ and 
placed in the appropriate testing apparatus (see ‘7.3 Behavioural Testing’ section below). 
Following testing, subjects were returned to their home cages. 
7.3 Behavioural Testing 
Behavioural testing occurred 20 minutes following drug treatment (one test per day, 
on two non-consecutive testing days). All subjects were tested using two behavioural testing 
paradigms: the open field (OF), and the elevated plus maze (EPM). The order in which the 
subjects experienced the two behavioural tests was counterbalanced to account for any 
potential order or learning effects, and the two testing days were always separated by a rest 
day. All tests were performed in one of two experimental rooms under low-light conditions. 
Immediately following each individual subject’s test, the apparatus was thoroughly 
cleaned with a Sani Express 4% solution to attenuate confounding odour cues from previous 
trials. Further to this, on the days when both males and females were tested in the same 
apparatus, males were always tested first. This was because it has been suggested that males 
may be particularly sensitive to odour cues left behind by females even after thorough 
cleaning (Hughes, 2007).  
All tests were observed via a small CCTV camera suspended over the apparatus. This 
allowed the experimenter to view the subjects from a television monitor some distance away 
in the room (i.e., so they weren’t standing over the apparatus) and reduced the likelihood of 
their presence affecting the subjects’ behaviour. The footage of each trial was recorded to a 






7.3.1 Open Field Testing. The open field apparatus and procedure were replications 
of those described for Experiment 1 (See 3.3.1 Open Field – Apparatus, and 3.3.2 Open Field 
– Procedure). The only notable differences were that the trials were not coded live but rather 
recorded for later observation. This was due to the addition of a number of behavioural 
measures that necessitated multiple viewings of the recordings. The same anxiety-related 
measures recorded in Experiment 1 were again observed, including: ambulation, walking, 
rearing, grooming, freezing, corner occupancy, and center occupancy (defecation was 
omitted from this experiment). In addition, using a modified version of the Canales and 
Grabiel (2000) procedure, four measures of stereotypy were also coded and assessed: head 
swaying, gyration, thigmotaxis, and stereotypy total. ‘Head swaying’ represented the uniform 
and repetitive swaying of the head, from left to right (a behaviour visually distinct from the 
‘normal’ head movements associated with smelling and exploration). ‘Gyration’ involved the 
subjects turning in tight, full circles, often repetitively (i.e., spinning on the spot). 
‘Thigmotaxis’ was a measure of the subjects’ tendency to trace the outside of the apparatus, 
moving along the edges of the open field and continuing to follow the line of the ‘walls’. It 
was thought that high levels of thigmotaxis might potentially confound other measures such 
as corner occupancy. The final measure, ‘stereotypy total’, was a composite score comprised 
of both head swaying and gyration (thigmotaxis was excluded as it proved a difficult 
behaviour to quantify as distinct from ‘normal exploration’). As with the procedure outlined 
for the anxiety-measures, every 3 seconds the experimenter recorded which (if any) of these 
stereotypy measures the subjects were engaging in. It was then possible to calculate the 
relative time spent engaging in these behaviours over the 5 minutes of testing.  
7.3.2 Elevated Plus Maze Testing. Similar to the open field testing described above, 
the elevated plus maze apparatus and procedure were the same as for Experiment 1 (see 3.3.3 




recording of the trials for later coding, and the inclusion of stereotypy measures. Percent 
entries into the open arms, percent observations in the open arms, and number of entries into 
the closed arms were recorded, as were head swaying, gyration, and stereotypy total 
(thigmotaxis was not included for this test as the apparatus lacked a clear ‘boundary’ for the 
subjects to follow). 
7.4 Non-Behavioural Measures 
 In addition to the behavioural measures each subject’s weight and temperature were 
also recorded. Weight, in grams, for each subject was measured using standard laboratory 
scales on both of the two testing days (necessary to calculate the appropriate volume of 
solution to inject). The weight on the first day was subtracted from the weight on the second 
day to give a figure representing the change in weight for that subject over the three days of 
testing. It was then possible to compare weight change over this time between the different 
experimental groups.  
 The subjects’ temperature was also recorded, using a Braun IRT 4020 ThermoScan 
aural thermometer. Temperature recordings were taken on both testing days for all subjects. 
The first recording was taken at time of drug (or saline) administration, and the second was 
taken immediately following behavioural testing (i.e., 25 minutes following drug 
administration). The first temperature was subtracted from the second to give a figure 
representing the change in temperature, and this difference score was averaged for each 
subject across both testing days. The final figure then was an average temperature change (in 









 Unless otherwise stated, all measures were statistically analysed using separate 4 
(drug) × 2 (sex) ANOVAs, and Fisher PLSD post hoc comparisons (p<0.05). Where 
appropriate, ANCOVAs were also utilised in order to test the significance of a given result 
after accounting for a potentially confounding co-variable. All analyses were performed 
using Statistica 12 software by StatSoft©. 
 No animals required exclusion from testing or analysis, so the data from all 64 
subjects were used in the various statistical analyses. 
8.1 Open Field Results – Anxiety Measures 
 The effects of mephedrone on the various anxiety measures in the open field are 
presented in Figure 9. As can be seen, as the mephedrone dose increased: ambulation and 
walking behaviours increased; while rearing, freezing, and grooming behaviours decreased. 
Mephedrone appears to have increased center occupancy as well, with this increase in 
behaviour peaking at 10mg/kg. Corner occupancy shows the inverse, with mephedrone 
decreasing the frequency of the behaviour most notably at 10mg/kg. The effects of 
mephedrone on center and corner occupancy remained significant after controlling for 












Figure 9. Mean ± S.E.M. frequencies for (A) ambulation, (B) walking, (C), rearing, (D) freezing, (E) 
grooming, (F) center occupancy, and (G) corner occupancy recorded in the open field following 
treatment with mephedrone. Data represents results for both male and female rats combined. 
*Significantly different from control group (p < 0.05). 
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8.2 Open Field Results – Stereotypy Measures 
 Four stereotypy measures observed in the open field are presented in Figure 10. As 
can be seen, mephedrone significantly increased the frequency of all four measures. 1mg/kg 
did not significantly increase either the head swaying or gyration measures separately, though 
when combined in the stereotypy total measure even this low dose creates a significant effect.   
 
Figure 10. Mean ± S.E.M. frequencies for (A) head swaying, (B) gyration, (C), thigmotaxis, and (D) 
stereotypy total recorded in the open field following treatment with mephedrone. Data represents 
results for both male and female rats combined. 
*Significantly different from control group (p < 0.05). 
a,b,cGroups with superscripts in common are significantly different (p < 0.05).  
 
 After controlling for ambulation as a co-variable, the effects of mephedrone remained 
significant for head swaying [F(3,58) = 38.62, p<0.001], gyration [F(3,58) = 22.17, p<0.001], 
and stereotypy total [F(3,58) = 131.09, p<0.001]; whereas thigmotaxis was no longer 
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The stereotypy total measure had a significant drug × sex interaction, F(1,56) = 5.11, 
p <0.01. Figure 11 shows that male and female subjects’ stereotypy total scores both 
appeared to have increased correspondingly up to 10mg/kg of mephedrone. At 20mg/kg the 
males’ scores appear not to have changed, whereas the females’ continued to increase. 
 
 
Figure 11. Mean ± S.E.M. frequencies for males and females on the stereotypy measure in the open 
field following treatment with four doses of mephedrone.  
*Significantly different from control group for that sex (p < 0.05). 









Dose 0 1 10 20
Mean M 19.75 28.5 61.75 64.75
SEM M 5.39 5.76 9.07 10.43
Mean F 20.88 28 66.38 82.88





























8.3 Elevated Plus Maze Results – Anxiety Measures 
 Three measures of anxiety in the elevated plus maze are displayed in Figure 12. As 
can be seen, mephedrone decreased percent observations in and entries into the open arms of 
the maze, though this effect is only significant for 20mg/kg. None of the doses of 
mephedrone had any significant effect on the number of entries into the closed arms. 
 
 
Figure 12. Mean ± S.E.M. frequencies for (A) percent observations in the open arms, (B) percent 
entries into the open arms, and (C) entries into the closed arms of the elevated plus maze following 
treatment with mephedrone. Data represents results for both male and female rats combined. 
*Significantly different from control group (p < 0.05). 
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8.4 Elevated Plus Maze – Stereotypy Measures 
 Similar to measures in the open field; head swaying, gyration, and stereotypy total 
were recorded in the elevated plus maze as measures of stereotypy. Figure 13 shows that as 
mephedrone dose increased, all three of these behavioural measures increased in frequency. 
Head swaying and gyration showed no significant effect at 1mg/kg, though when combined 




Figure 13. Mean ± S.E.M. frequencies for (A) head swaying, (B) gyration, and (C) stereotypy total 
recorded in the elevated plus maze following treatment with mephedrone. Data represents results for 
both male and female rats combined. 
*Significantly different from control group (p < 0.05). 
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8.5 Sex Differences 
 The overall sex differences for each of the behavioural measures examined are 
presented in Table 3. As can be seen, in the open field female subjects travelled significantly 
further distances (ambulation) than males, froze less, and displayed more total stereotypy 
behaviours. In the elevated plus maze, females spent significantly more time than males 
stereotypically turning in circles (gyration). On the measures that did not reach statistical 
significance, most of the results suggest that females generally performed those behaviours 
more frequently than males.  
Table 3 
Means, S.E.Ms, and ANOVA results for main effects of Sex on all measures.  
 Sex of Rats  
Measure Male Female F(1,56) 
Open Field    
Ambulation 58.00(±3.41) 70.53(±3.45) 8.98** 
Walking 74.09(±3.73) 75.56(±3.80) 0.48 
Rearing 14.75(±2.74) 17.31(±3.09) 3.28 
Freezing 10.69(±1.88) 6.22(±1.43) 4.12* 
Grooming 0.47(±0.25) 0.91(±0.51) 0.66 
Centre Occupancy 26.06(±2.90) 25.62(±3.50) 0.01 
Corner Occupancy 25.66(±2.80) 27.13(±2.76) 0.17 
Head Swaying 8.22(±1.79) 5.25(±1.34) 2.89 
Gyration 15.44(±2.54) 16.34(±3.57) 0.08 
Thigmotaxis 20.03(±2.38) 27.94(±3.82) 3.29 
Stereotypy Total 43.69(±3.80) 49.53(±4.80) 9.74** 
Elevated Plus Maze    
% Entries in Open Arms 0.45(±0.04) 0.50(±0.04) 0.70 
% Observations in Open Arms 0.46(±0.05) 0.53(±0.05) 1.26 
Entries into Closed Arms 5.16(±0.43) 8.13(±1.44) 3.90 
Head Swaying 20.00(±3.65) 17.56(±3.74) 0.83 
Gyration 11.25(±1.13) 17.81(±2.33) 11.54** 
Stereotypy Total 31.25(±4.30) 35.38(±5.13) 2.44 










8.6 Non-Behavioural Measures 
 The average difference in the subjects’ weight between the two testing days is 
displayed in Figure 14. The results suggest that subjects receiving 1mg/kg of mephedrone 
gained significantly more weight than control rats, as well as more than those administered 
higher doses. Those subjects administered 10mg/kg and 20mg/kg showed no significant 




Figure 14. Mean ± S.E.M. results for weight difference (in grams) over the 3 days of testing. Data 
represents results for both male and female rats combined. 
*Significantly different from control group (p < 0.05). 
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Mean 0.75 3.94 -0.25 1.38





























 The changes in each subjects’ temperature 20 minutes following drug administration 
were recorded and averaged across the two testing days. Figure 15 displays the average 
difference across experimental groups. As can be seen, the 20mg/kg group showed a 
significantly greater increase of temperature than the 1mg/kg and 10mg/kg groups, though 
none were significantly different from the control group.  
 
 
Figure 15. Mean ± S.E.M. results for average temperature difference (in degrees Celsius), 20 minutes 
following treatment with mephedrone. Data represents results for both male and female rats 
combined. 
*Significantly different from control group (p < 0.05). 
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 Experiment 2 examined the anxiety-like behaviours of male and female rats following 
acute treatment with 1, 10, or 20mg/kg of mephedrone, or isotonic saline. In addition, 
stereotypy behaviours were assessed in both the open field and elevated plus maze tests. The 
results generally supported Hypothesis 1; that mephedrone would produce more anxiety-like 
behaviours as dose increased, and in a pattern similar for both male and female subjects. The 
stereotypy measures also supported Hypothesis 2; that mephedrone would produce more 
stereotypy behaviours as the dose increased, and that males and females would express these 
behaviours differently. 
9.1 Open Field Findings 
 9.1.1 Anxiety-like behaviours. Mephedrone produced a significant increase in 
ambulation and walking behaviours in the open field, consistent with results seen in 
Experiment 1, and likely a result of the direct psychostimulant effects of mephedrone. 
Treatment with mephedrone also resulted in decreased rearing, and grooming behaviours, 
which are both indicative of increased anxiety. These decreases trended down as the 
mephedrone dose increased, displaying a dose-dependent anxiogenic effect consistent with 
the first part of Hypothesis 1.  
Mephedrone also significantly decreased the frequency of freezing behaviours in the 
open field. Decreased freezing is usually indicative of less anxiety, so this finding is at odds 
with the other measures and the predicted outcome. One explanation for this result is that the 
stimulant effects of mephedrone increased general locomotor activity, a theory supported by 
the results of the ambulation and walking measures, as well as previous research into similar 
drugs (e.g., Gatch et al., 2015; Sahakian et al., 1975). This general hyperactivity then would 
inherently result in less freezing behaviours or standing still, as the animals spend a greater 




The center and corner occupancy measures also had unexpected results in the open 
field. If mephedrone produces a dose-dependent anxiogenic effect as predicted by Hypothesis 
1 (and supported by the results of other behavioural measures) we would expect to see center 
occupancy trending downwards and corner occupancy trending upwards with higher doses. 
Instead, the results for center occupancy show an increase at 10mg/kg, then a decrease at 
20mg/kg. This finding is unlikely to be an artefact of the data as it is perfectly mirrored in the 
corner occupancy results as well (a decrease at 10mg/kg, followed by an increase at 
20mg/kg).  
There are really two elements to these findings that need to be explained: (A) why did 
center occupancy increase (and corner occupancy decrease) at 10mg/kg, which was counter 
to our predictions? And (B) why then did this increase (and decrease, respectively) lessen at 
20mg/kg? The second element (B) may be easier to answer with the current data: the 
stereotypy results from the open field (discussed in the next section) show that the frequency 
of all stereotypy behaviours increased with higher doses of mephedrone. In particular, 
thigmotaxis (running along the walls of the apparatus, ‘tracing’ the outside edges) was 
significantly increased at the highest dose. This suggests that those subjects treated with 
20mg/kg spent more time than subjects treated with lower doses running around the outside 
of the open field, which would both decrease their chances of being observed in the center 
squares and increase the chance of being observed in the corners. Whatever factor produced 
the increase and decrease in center and corner occupancy (respectively) at 10mg/kg can then 
be thought of as being confounded by stereotypy at 20mg/kg.  
How then do we explain the initial increase and decrease (A)? Three explanations that 
may individually or in combination, plausibly explain the current findings are therefore 
suggested: 1) as with the explanation for (B), stereotypy may have confounded these 




(turning/running in tight circles) was. Subjects gyrating over the area of two or more grid 
squares would be much more likely to be observed sometimes occupying a center square, 
particularly as the low corner occupancy and thigmotaxis scores suggest that said gyration 
was not frequently occurring near the corners or sides of the apparatus. 2) While 1mg/kg may 
not be psychoactive enough to produce a given effect, and 20mg/kg may be ‘too active’ (i.e., 
induces stereotypy behaviours significant enough to confound attempts to measure the 
effect), perhaps 10mg/kg is in the ‘Goldilocks’ zone and allows us to observe an effect of 
mephedrone that would otherwise be missed (i.e., by Experiment 1, which had no dose 
between 1 and 20mg/kg). The increase in center occupancy (and decrease in corner 
occupancy) could then be explained by other known or suspected effects of mephedrone, 
such as: disinhibition/increased risk taking, increased locomotor activity, elevated mood, or 
confusion. 3) A final explanation for the findings is simply that mephedrone may produce 
different effects, not simply different degrees of the same effect, at different doses (e.g., an 
anxiolytic effect at low doses, and an anxiogenic effect at higher doses). This latter 
explanation is difficult to substantiate with the current data, though is plausible and supported 
by previous research that has found similar synthetic cathinones to have different effects at 
different doses (Coppola & Mondola, 2012b; Zourob, 2011). 
9.1.2 Stereotypy behaviours. Mephedrone produced a significant increase in all four 
stereotypy measures examined in the open field. Head swaying, gyration, thigmotaxis, and 
stereotypy total (a composite of head swaying and gyration measures) all display a trend of 
increasing frequencies of stereotypy behaviours as mephedrone dose increases, supporting 
the first part of Hypothesis 2. In all of the measures except the stereotypy composite, 1mg/kg 
did not significantly increase the frequency of the behaviours relative to control. This 




rather that there is likely a ‘threshold’ dose after which these behaviours are present and can 
be reliably measured. 
A significant dose × sex interaction was found on the stereotypy total measure. Up to 
10mg/kg both males and females displayed the same pattern of stereotypy behaviours (i.e., a 
dose-dependent increase) though at 20mg/kg females’ stereotypy behaviour increased further, 
while male stereotypy levels plateaued. This suggests that at higher doses of mephedrone the 
observable stereotypic effects are different for males and females, supporting the second part 
of Hypothesis 2.   
9.2 Elevated Plus Maze Findings 
9.2.1 Anxiety-like behaviours. Mephedrone produced a significant decrease in 
percentage entries into the open arms of the elevated plus maze, and also in the percentage 
time spent in the open arms. These results are indicative of increased anxiety and are 
consistent with results reported in other studies examining similar psychoactive compounds 
(Cruz et al., 1994; Martinez et al., 2002; Pellow et al., 1985; Silva & Brandao, 2000). The 
decrease in both measures observed with mephedrone treatment is more pronounced at higher 
doses of the drug (i.e., there is a dose-dependent decrease), supporting the first part of 
Hypothesis 1. While these findings are consistent with our predictions (based on previous 
research), they are different to those found in Experiment 1 (which detected no significant 
differences in the EPM). It is unclear at this time why this particular test produced different 
findings in the current experiment, particularly as the methodology was replicated exactly. 
Entries of closed arms were recorded as a control measure to assess general locomotor 
activity, uncontaminated by anxiety (Cruz et al., 1994). There were no significant differences 
in the number of entries into the closed arms of the maze with the various mephedrone doses 




unlikely to have been contaminated by general locomotor activity (e.g., simply entering more 
maze arms overall due to hyperactivity). 
9.2.2 Stereotypy behaviours. As in the open field results mephedrone produced a 
significant increase in all of the stereotypy measures recorded in the elevated plus maze. 
Head swaying and gyration (thigmotaxis was not recorded in the EPM) both increased in 
frequency as the mephedrone dose increased, as did the stereotypy total measure (the latter 
being unsurprising as this measure is a composite of the other two). Taken together, these 
results support the first part of Hypothesis 2.  
9.3 Sex Differences 
 9.3.1 Anxiety-like behaviours. Unsurprisingly, females displayed significantly more 
ambulation, and less freezing behaviours than males. These findings are consistent with the 
known general activity differences between the sexes, and with results seen in Experiment 1. 
None of the other anxiety-related measures displayed significant sex differences, suggesting 
that males and females performed these behaviours comparably across the range of 
mephedrone doses examined. Taken together these results further support the second part of 
Hypothesis 1. 
 9.3.2 Stereotypy behaviours. In the open field, females were significantly higher on 
the stereotypy total measure than males, which is perhaps surprising given that the there were 
no significant differences in the two measures that comprise this composite score (head 
swaying and gyration). While the differences were not significant, females displayed more of 
the ‘active’ stereotypy behaviours than males (i.e., more gyration, less head swaying) and 
perhaps these differences were amplified when composited into the stereotypy total score. In 
the elevated plus maze females exhibited significantly more gyration than males, whereas 
there was no significant difference on the head swaying measure. The stereotypy total 




compromising statistical power of the composite score. Taken together these results tend to 
support the second part of Hypothesis 2 that males and females would differ in their 
expression of stereotypy. It appears that generally females express their stereotypy in more 
‘active’ forms than do males, within the current study. 
9.4 Non-Behavioural Measures 
 Over the three days of testing, those subjects treated with 1mg/kg of mephedrone 
gained significantly more weight than control animals, and also more than those subjects on 
higher doses of mephedrone. It is unclear why the low-dose subjects saw this increase in 
weight gain; it could be that mephedrone impacts appetite or satiety, and that it does so 
differently at different doses. This would be an interesting area for future investigation. 
 The difference in the aural temperature of subjects between the time of drug injection 
and the completion of testing (i.e., 25 minutes later) was averaged for each subject to give the 
temperature difference measure. The results showed no significant differences from control 
for any of the doses of mephedrone. The lack of findings here may reflect measurement error, 
or natural variation in the data. Relative to Experiment 1 (which found a significant dose-
dependent increase in temperature) the current study had smaller sample sizes (n=8, 
compared to n=10 from Experiment 1) and fewer tests to average the difference scores across 
(2 tests compared to 4 in Experiment 1). It is possible that these methodological differences 
contributed to the current study lacking significant statistical power to detect an effect of 
temperature difference.     
9.5 Limitations and Future Research 
 As with in Experiment 1, the presence of stereotypy is still a significant limitation in 
this study to accurately measuring anxiety-like behaviours. Stereotypy behaviours appear to 
confound some behavioural measures, particularly at higher doses. This study quantified 




behaviours with regard to the stereotypy measures, lending some additional validity and 
evidence to the conclusions drawn both here and in Experiment 1. Given the apparent strong 
association between anxiety and stereotypy it may not be possible to separate these two in 
behavioural testing, in which case it will be important for future research to similarly account 
for the potential confound when interpreting their findings. 
 The current study had a sample size of 8 subjects per experimental group, whereas for 
Experiment 1 this sample size was 10. A sample size of 8 should provide sufficient statistical 
power to detect an effect of treatment, as has been successfully used in previous studies 
employing similar methodologies (e.g., Anderson & Hughes, 2008; Thompson, 2012), 
though it stands to reason that the statistical power of Experiment 1 would have been 
comparatively greater, so this should be factored in to any understanding of differences in 
findings between the two studies. 
 The current study added a 10mg/kg dose of mephedrone to fill a ‘gap’ not measured 
in Experiment 1. This decision was further justified when the results showed there were a 
number of effects found ‘uniquely’ at 10mg/kg that Experiment 1 had not detected. It appears 
as if there may be two critical ‘thresholds’ with increasing mephedrone doses: (1) the point at 
which stereotypy behaviours begin and can be reliably observed/recorded, and (2) the point at 
which these stereotypy behaviours are significant enough that they potentially confound 
anxiety-related measures. The current study suggests that threshold (1) is likely to be near 
10mg/kg, and threshold (2) is likely to be near 20mg/kg. It would be interesting for future 
research to examine more doses between 1 and 20mg/kg to see if these ‘thresholds’ can be 
observed and more accurately defined. 
 Both Experiments 1 and 2 have established evidence that mephedrone produces 
anxiety-like behaviours following acute treatment. Future studies should also examine any 




behaviours, and the long-term effects of acute mephedrone treatment (i.e., are there any 
lasting effects on behaviour observable later in life). In particular, does mephedrone produce 
any behavioural teratological effects during specific developmental periods such as 
adolescence (the period during which humans are most likely to begin experimenting with 
drugs and alcohol)? 
9.6 Conclusion 
 The results from Experiment 2 appear to support both parts of Hypothesis 1 that 
mephedrone would have a dose-dependent anxiogenic effect, and that this effect would be 
similar for males and females. The findings also support both parts of Hypothesis 2 that 
mephedrone would have a dose-dependent effect on stereotypy behaviours, and that this 
effect would be different for males and females. The results seem to suggest that the dose-
response pattern for mephedrone may have two ‘thresholds’: the point at which stereotypy 
behaviours begin, and the point at which stereotypy confounds other measures. Given that 
stereotypy may be impossible to separate from anxiety in behavioural tests, understanding the 
relationship between the two is an important factor for interpreting the results of these studies 













10.0 Experiment 3 – Adolescent Teratology and Environmental Enrichment 
10.1 Teratology Overview  
Teratology is a field of study that examines the causes, mechanisms, and patterns of 
abnormal development (Ujhazy, Mach, Navarova, Brucknerova, & Dubovicky, 2012). 
Exposure to certain drugs, chemicals, viruses, bacteria, parasites, radiation, and maternal 
stress (i.e., ‘teratogens’) during critical developmental periods can disrupt normal 
development and result in growth retardation, delayed mental development, or other 
structural malformations (Ujhazy et al., 2012; Wilson, 1973; Wilson & Fraser, 1977). 
Perhaps the best-known example of teratological outcomes in humans is the thalidomide 
tragedy of the late 1950’s and 1960’s. An immunomodulatory drug, thalidomide was sold 
over-the-counter to pregnant women to relieve the nausea associated with morning sickness. 
Shortly afterwards, thousands of infants were born with malformed limbs (‘phycomelia’), 
eyes, and hearts, and many did not survive (Fintel, Samaras, & Carias, 2009; Miller, 1991; 
Ujhazy et al., 2012). Following the disaster, regulations over the development and use of 
drugs were significantly amended (Fintel et al., 2009; Heaton, 1994). While thalidomide was 
one of the more high-profile teratological events of modern times, a number of other 
significant events are displayed in Table 4. 
Accordingly, ‘behavioural teratology’ refers to the study of abnormal behavioural 
sequelae resulting from exposure to teratogens during critical developmental periods. 
Disrupted growth or damage of the developing brain can have long-lasting effects on 








Table 4. Significant Teratological Events in Modern History (Ujhazy et al., 2012) 
Year Teratological Event 
1905 The first experimentally induced developmental toxicity in mammals. Embryonic 
lethality induced by X-rays in cats. 
1921 The first experimentally induced teratogenicity in mammals. Disorders in limbs in pigs 
induced by lipid diet. 
1929 He first description of malformations in humans caused by exogenous factors. 
Microcephalia caused by X-ray irradiation of the pelvis. 
1935 Recognition of food deficiency leading to malformations in animals. Eye disorders in 
pigs due to hypovitaminosis A. 
1937 Hormones causing alteration in sexual differentiation in animals. Masculinisation of 
female foetuses in mice due to the action of androgens. 
1941 Report on virus-induced human malformations. Rose-rash induced eye disorders. 
1944 The first evidence of postnatal effect following prenatal administration of a chemical 
substance. Decreased learning ability in rats caused by the administration of sodium 
bromide. 
1948 General recognition of chemically induced teratogenicity. Experiments with alkylating 
agents and trypan blue. 
1952 The first report on malformations caused by drugs in humans. Multiple malformations in 
foetuses caused by aminopterin. 
1959 The first report on malformations induced by environmental pollutants. Disorders of the 
central nervous system and dentition caused by methyl mercury. 
1961 Thalidomide-induced embryopathy 
  
 A critical factor in the susceptibility of an organism to teratogenesis is the 
developmental stage during which they are exposed to the teratogen. Generally, organisms 
are most susceptible to teratogenic influences during periods of rapid cell differentiation, 
growth, and development. Accordingly, in mammals the most vulnerable periods of 
development are the prenatal and lactational stages, as well as adolescence (Rice & Barone 
Jr, 2000). Exposure to teratogens during these periods can have long-lasting or permanent 
effects on development.    
10.2 Adolescence 
 Adolescence can be defined as the developmental period transitioning from 
immaturity and dependence, to maturity and independence (Rowse, 2010; Spear, 2007). It 
includes, but is not synonymous with puberty and its associated physiological changes and 
growth spurt. Of specific interest to psychologists are the behavioural features associated 
with adolescence, which include: increased novelty seeking, increased risk taking behaviours, 




with drugs and alcohol (Irwin Jr, 1989; La Greca, Prinstein, & Fetter, 2001; Trimpop, Kerr, 
& Kirkcaldy, 1999). The adolescent brain in still developing (Spear, 2007), and while the 
brain does not grow dramatically in size during adolescence (having reached 90% of its total 
adult size by age six); myelination (white matter production that increases the speed of neural 
signals), and synaptic pruning (the selective process whereby often-used neural connections 
are strengthened, while unused connections are eliminated) significantly reorganise the brain 
throughout this period (Casey, Tottenham, Liston, & Durston, 2005; Rowse, 2010). The 
timing of the adolescent period is often difficult to define. The developmental period in 
humans is often described as ranging from 12-18 years of age, though some features may 
begin as early as 8-10 (especially in females), and some may last as late as until 25 
(especially in males) (Spear, 2007).  
 10.2.1 Adolescence in Rats. The developmental stage of adolescence is not unique to 
humans, with other species exhibiting comparable physiological and behaviour changes. In 
addition to undergoing the hormonal changes and growth spurt associated with puberty; 
adolescent rats seek more novelty, display greater social conditioned place preference (CPP), 
and are more inclined to voluntarily consume alcohol compared to adults (Spear, 2007). The 
timing of the adolescent period in rats is also as comparably difficult to define as it is in 
humans. Researchers have conservatively classified adolescence as ranging from 28 to 42 
postnatal days, based on the timing of the growth spurt, puberty, and behavioural changes 
(Spear, 2000).  However, similar to the relative differences in humans; some features of 
adolescence may be seen as early as postnatal day 23 (especially in females), and other signs 
can still be observed as late as postnatal day 55 (especially in males) (Spear, 2007). Studies 
involving adolescence in rats therefore need to be selective about the precise time-period 





10.3 Environmental Enrichment 
 Environmental enrichment has been shown to produce a number of positive 
physiological and behavioural outcomes in both humans and animals (Frick & Fernandez, 
2003; Shimamura, Berry, Mangels, Rusting, & Jurica, 1995). Early exposure to enriched 
social, physical activity-related, and perceptual stimulation has beneficial effects on both 
brain and behavioural development (Renner & Rosenzweig, 1987). It has been suggested that 
such enrichment induces a number of neurochemical changes in the brain such as increased 
cortical thickness, synaptic contacts, and number of dendritic spines; resulting in greater 
neural plasticity and thus improved learning and memory (Rosenzweig & Bennett, 1995; van 
Praag, Kempermann, & Gage, 2000).  
In studies using rodents, this type of enrichment is usually accomplished via the 
provision of objects or toys designed to encourage exploration, manipulation, and physical 
activity; to the home cages of group-housed subjects. Relative to rats housed in ‘standard’ 
cages, these ‘enriched’ rats have been shown to exhibit greater learning and memory 
capacity, as well as decreased anxiety-like behaviours in behavioural tests (Benaroya-
Milshtein et al., 2004; Hughes & Collins, 2010; Laviola et al., 2004).   
10.4 Experiment 3 Aims and Hypotheses 
 Experiment 3 sought to examine the teratological effects of adolescent mephedrone 
use on long-term anxiety-like behaviour. Previous studies have found that the use of 
psychomotor stimulants during adolescence produces anxiogenic effects detectable, 
following abstinence, later in life (e.g., Aitchison & Hughes, 2006; Anderson & Hughes, 
2008; Thompson, 2012). This suggests that these types of drugs can have long-lasting or 
permanent effects when used specifically during critical developmental periods. The results 
of both Experiment 1 and 2 suggest that mephedrone has acute anxiogenic properties, but the 




treatment of adolescent rats with mephedrone and then measured anxiety-like behaviours 
later in adulthood, with a view to identifying any lasting impacts of mephedrone exposure. 
 In addition, Experiment 3 also sought to examine the effects of environmental 
enrichment on anxiety-like behaviours, specifically if the anxiolytic effects of enrichment 
would mitigate any anxiogenic effects of mephedrone. If so, this information would be useful 
in understanding and building resistance and resilience to some of the harmful and long-
lasting effects of drug use during adolescence.  
 It was hypothesised that those rats treated with mephedrone during adolescence would 
display more anxiety-like behaviours in adulthood compared to the control group (Hypothesis 
1). It was also hypothesised that, overall, environmentally enriched rats would display fewer 
anxiety-related behaviours compared to rats reared in ‘standard’ cages (Hypothesis 2). It was 
further hypothesised that of the rats treated with mephedrone, those raised in ‘enriched’ 
environments would display fewer anxiety-like behaviours than those raised in ‘standard’ 

















 The subjects used in this study were 32 male and 32 female PVG/c hooded rats bred 
in the Animal Facility of the Department of Psychology at the University of Canterbury, 
Christchurch, New Zealand. Following weaning at PND30 (Postnatal day 30) half of the 
animals (16 males and 16 females) were randomly assigned to the ‘enriched’ caging 
condition (see 11.2 Environmental Enrichment below) and the other half to the ‘standard’ 
caging condition. All subjects were housed in 550 x 360 x 220mm-high plastic cages in 
groups of four same-sexed animals. They were kept on a 12-hour light/dark cycle (lights on 
at 0800 hours) at an ambient temperature of 22 ± 2°C (with humidity of 48% ± 10%). All 
subjects had free access to standard laboratory food and drinking water at all times. The care 
and experimental treatment of subjects complied with Parts 5 (Code of Welfare) and 6 (Use 
of Animals in Research, Testing and Teaching) of the New Zealand Animal Welfare Act, 
1999 and had been approved by the Animal Ethics Committee of the University of 
Canterbury (See Appendix H). 
11.2 Environmental Enrichment 
The subjects assigned to the enriched caging condition were provided with four 
different objects or ‘toys’ to interact with in their home-cage. These enrichment objects were 
chosen at random from a selection containing items such as glass jars, plastic tunnels, cups, 
balls, small wooden toys, household utensils, small chains, and cardboard boxes (see Figure 
I1 in Appendix I). The objects were chosen to promote and encourage exploration, 
manipulation, and physical activity (as used by Hughes & Collins, 2010; Thompson, 2012). 
The objects in each cage were changed once per week with another four randomly chosen 
from the collection. This was to help ensure that all subjects had different and ‘novel’ toys to 




more than once. The subjects assigned to the ‘standard’ caging conditions were housed in 
identical cages, though were not supplied with toys or objects to interact with (see Figure I2 
in Appendix I). 
11.3 Mephedrone Treatment 
  Half of the subjects in each caging condition (8 males and 8 females) were randomly 
assigned to a drug treatment condition, and the other half to a saline control. Those in the 
drug treatment condition received mephedrone at a dose of 20mg/kg, a dose found to produce 
significant effects in both Experiments 1 and 2. The mephedrone used in this study was 
synthesised on-site in the Department of Psychology at the University of Canterbury. The 
resulting mephedrone 98% salt was dissolved daily in isotonic saline to create a 20mg/kg 
solution. These doses were then administered to the subjects via intraperitoneal (I.P.) 
injections in a volume of 1ml/kg.  
Beginning on PND45 the subjects were treated with either mephedrone or isotonic 
saline (for the control group) once per day, for 10 consecutive days. PND45 to PND55 is a 
developmental period that has been used previously in similar studies to approximate human 
adolescence in rats (Aitchison & Hughes, 2006; Anderson & Hughes, 2008; Thompson, 
2012), and this pattern of treatment was designed to represent chronic use during this time.  
11.4 Behavioural Testing 
Behavioural testing began when the subjects reached adulthood at approximately 
PND110. All subjects were tested once per day, using three behavioural testing paradigms: 
the open field, the light/dark box, and the elevated plus maze. The order in which the subjects 
experienced the three behavioural tests was counterbalanced to account for any potential 
order or learning effects, and the three testing days were always separated by a ‘rest’ day. All 




Immediately following each individual subject’s test, the apparatus was thoroughly 
cleaned with a Sani Express 4% solution to attenuate confounding odour cues from previous 
trials. Further to this, on the days when both males and females were tested in the same 
apparatus, males were always tested first. This was because it has been suggested that males 
may be particularly sensitive to odour cues left behind by females even after thorough 
cleaning (Hughes, 2007).  
All tests were observed via a small CCTV camera suspended over the apparatus. This 
allowed the experimenter to view the subjects from a television monitor some distance away 
in the room (i.e., so they weren’t standing over the apparatus) and reduced the likelihood of 
their presence affecting the subjects’ behaviour.  
11.4.1 Apparatus’ and Procedure. The open field, light/dark box, and elevated plus 
maze and procedures were the same as for Experiment 1 (See 3.3 Behavioural Testing). For 
the open field, the same anxiety-measures recorded in Experiment 1 were again observed, 
including ambulation, walking, rearing, grooming, freezing, corner occupancy, and center 
occupancy (as with Experiment 2, defecation was omitted from this experiment). In the 
light/dark box; observations in the light side, entries into the light side, first emergence 
latency, and number of prior emergences were recorded. In the elevated plus maze, percent 
observations in the open arms, percent entries into the open arms, and number of entries into 
the closed arms were all recorded. Stereotyped behaviours were not assessed in this 
experiment, as the testing occurred weeks after drug administration rather than immediately 
afterwards (as with Experiments 1 and 2) where acute drug effects (like stereotypy) might be 
observed.      
11.5 Non-Behavioural Measures 
 In addition to the behavioural measures, each subject’s weight at adolescence and at 




standard laboratory scales on each of the ten treatment days (necessary to calculate the 
appropriate volume of solution to inject) as well as on the final testing day. The average 
weight during treatment (‘adolescence’) was subtracted from the final weight (‘adulthood’) to 
give a figure representing the change in weight for that subject over the two months between 
treatment and testing. It was then possible to compare weight gain over this time between the 
























 Unless otherwise stated, all measures were statistically analysed using separate 2 
(drug) × 2 (enrichment) × 2 (sex) factorial ANOVAs, and Fisher PLSD post hoc comparisons 
(p<0.05). Where appropriate, ANCOVAs were also utilised in order to test the significance of 
a given result after accounting for a potentially confounding co-variable. All analyses were 
performed using Statistica 12 software by StatSoft©. 
 Subject number 20 (male, enriched, saline control) was found dead in its cage 
between the treatment and testing phases of the experiment. The death was deemed not to be 
connected to the experiment, and none of its cage-mates showed any abnormal behaviours or 
signs. Nevertheless, as it died before the testing phase it was clearly not able to be included in 
the data set.  
12.1 Open Field Results  
 The main effects for both drug treatment and enrichment condition, along with means 
and standard errors for all of the open field measures are displayed in Table 5. As can be 
seen, the subjects treated with mephedrone during adolescence displayed significantly less 
ambulation and rearing behaviours, and more freezing behaviours compared to saline 
controls. Mephedrone’s effect on walking and grooming behaviours was negligible, as it was 
also for occupancy of the center or corner squares, with these measures failing to show any 
significant differences. Environmental enrichment significantly decreased the frequency of 
walking and freezing behaviours, and increased the frequency of rearing. Ambulation 
appeared to be decreased in the enriched relative to standard condition, although this 
difference was not statistically significant. Grooming, center occupancy, and corner 









Means, S.E.Ms, and ANOVA results for effects of Drug and Enrichment on all OF measures.  
 Drug Enrichment 
Measure Saline Mephedrone F(1,55) Standard Enriched F(1,55) 
Ambulationa 48.29(±1.94) 40.59(±1.92) 10.46** 46.06(±2.24) 42.65(±1.77) 2.46 
Walking 46.19(±1.48) 45.59(±1.13) 0.07 49.25(±1.18) 42.42(±1.13) 18.80*** 
Rearingb 41.85(±1.82) 33.97(±2.18) 10.81** 31.50(±1.78) 43.90(±1.81) 29.41*** 
Freezingc 8.48(±1.50) 16.06(±1.97) 11.18** 15.19(±1.86) 9.39(±1.76) 6.65* 
Grooming 3.97(±0.49) 4.38(±0.43) 0.32 4.06(±0.38) 4.29(±0.53) 1.02 
Centre Occupancy 10.06(±0.92) 10.00(±1.20) 0.00 9.84(±1.11) 10.23(±1.03) 0.05 
Corner Occupancyd 48.45(±2.06) 48.59(±2.41) 0.00 48.75(±2.26) 48.29(±2.24) 0.01 
*p < 0.05, **p < 0.01, ***p < 0.001 
aDrug × Enrichment interaction significant, F(1,55)  = 18.83, p <0.001 
bSex × Enrichment interaction significant, F(1,55) = 4.07, p <0.05 
cDrug × Enrichment interaction significant, F(1,55) = 5.72, p <0.05 
dDrug × Enrichment interaction significant, F(1,55) = 7.11, p <0.05       
 
  
As Table 5 indicates, there were a number of significant interactions found in the 

















As can be seen in (A), mephedrone significantly decreased ambulation in the open 
field for the standard caging condition, but not for the enriched condition. Similarly for 
freezing (C), mephedrone produced a significant increase in this behaviour in the standard 
caging but this effect was not found for the enriched condition. Corner occupancy (D) 
appeared to increase with mephedrone treatment for those in standard cages, whereas those in 
enriched cages showed a slight decrease in this behaviour when treated with the drug (though 
neither of these main effects were significant). The frequency of rearing in the open field (B) 
was different for males and females in different caging conditions. Female, standard subjects 
reared more often than male, standard subjects; whereas enriched males and females showed 
no significant difference. 
 
Figure 16. Mean ± S.E.M. frequencies for both standard and enriched caging conditions on (A) 
ambulation, (B) rearing, (C) freezing, and (D) corner occupancy in the open field. (A), (C), and (D) 
display results for both drug treatment and saline control groups (males and females combined). (B) 
displays results for males and females separately (drug treatment and control combined).    
*Significantly different from control (A,C,&D) or males (B) for that caging condition. (p < 0.05). 


















Mephedrone Dose (mg/kg/day) 















Mephedrone Dose (mg/kg/day) 












































12.2 Light/Dark Box Results 
 The effects of mephedrone and enrichment on measures in the light/dark box are 
displayed in Table 6. As can be seen, mephedrone significantly decreased the number of 
entries into the light side. Mephedrone also appears to have increased first emergence latency 
and decreased time spent in the light side of the apparatus, though these differences are not 
statistically significant. Enrichment significantly increased observations in the light side, and 
appears to have decreased first emergence latency, while increasing the number of prior 
emergences (though these measures are also non-significant). 
Table 6 
Means, S.E.Ms, and ANOVA results for effects of Drug and Enrichment on all LD measures.  
 Drug Enrichment 
Measure Saline Mephedrone F(1,55) Standard Enriched F(1,55) 
1st Emergence 
Latency (secs) 
21.77(±2.52) 29.72(±6.29) 1.27 26.91(±4.70) 24.68(±5.10) 0.10 
Entries Light Side 5.26(±0.33) 4.78(±0.29) 7.83** 5.34(±0.30) 5.42(±0.35) 0.42 
Observations Light 
Sidea 
36.61(±2.34) 32.44(±2.22) 2.00 30.31(±1.97) 38.81(±2.38) 8.12** 
Prior Emergences 0.71(±0.16) 0.75(±0.22) 0.01 0.47(±0.12) 1.00(±0.23) 3.99 
*p < 0.05, **p < 0.01, ***p < 0.001 
















As shown in Table 6 there was a significant drug × sex × enrichment interaction for 
the observations in the light side measure. This is displayed graphically in Figure 17. As can 
be seen; enriched, female subjects treated with mephedrone spent significantly less time in 
the light side of the light/dark box than saline controls but this effect was not true for 
enriched, male subjects (who showed no significant difference between drug and control 
groups). 
 
Figure 17. Mean ± S.E.M. frequencies for observations in the light side of the light/dark box. Data 
shown represents males and females, standard and enriched caging, and mephedrone and saline 
treatment conditions separately.  
*Significantly different from saline control for that sex and caging condition. (p < 0.05). 










Dose Standard Enriched Standard Enriched
Mean S 33 37 29.13 47.38
SEM S 4.77 3.65 4.13 3.81
Mean D 25.75 40.38 33.38 30.25



























12.3 Elevated Plus Maze Results 
 The effects of mephedrone and enrichment on measures recorded in the elevated plus 
maze are displayed in Table 7. As can be seen, neither mephedrone treatment nor 
environmental enrichment had a significant impact on the percentage entries into open arms, 
or relative time spent in open arms of the maze. Mephedrone and enrichment both 
significantly reduced the number of entries into open arms. 
 
Table 7 
Means, S.E.Ms, and ANOVA results for effects of Drug and Enrichment on all EPM 
measures. 
 Drug Enrichment 
Measure Saline Mephedrone F(1,55) Standard Enriched F(1,55) 
% Entries Open into 
Arms 
0.52(±0.02) 0.50(±0.02) 0.29 0.50(±0.02) 0.51(±0.02) 0.09 
% Observations in 
Open Arms 
0.56(±0.02) 0.51(±0.03) 1.60 0.55(±0.03) 0.52(±0.03) 0.48 
Entries into Closed 
Arms 
7.39(±0.33) 5.41(±0.34) 17.56*** 6.94(±0.36) 5.80(±0.37) 5.42* 


















12.4 Sex Differences 
 The overall sex differences for each of the behavioural measures examined are 
presented in Table 8. As can be seen, only one measure reached statistical significance: 
females were more ambulatory than males in the open field. The other measures show 
smaller or no differences, though the general pattern mostly reflects female subjects 
performing more of a given behaviour than males. 
Table 8 
Means, S.E.Ms, and ANOVA results for main effects of Sex on all measures.  
 Sex of Rats  
Measure Male Female F(1,55) 
Open Field    
Ambulation 40.87(±2.00) 47.78(±1.91) 9.47** 
Walking 45.87(±1.48) 45.91(±1.48) 0.02 
Rearing 36.29(±2.16) 38.88(±2.05) 0.91 
Freezing 13.48(±1.86) 11.22(±1.89) 0.79 
Grooming 4.35(±0.44) 4.00(±0.48) 0.33 
Centre Occupancy 9.61(±1.17) 10.44(±0.92) 0.29 
Corner Occupancy 47.90(±2.30) 49.13(±2.20) 0.13 
Light/Dark Box    
1st Emergence Latency (secs) 32.25(±6.35) 20.53(±2.62) 2.27 
Entries Light Side 5.26(±0.33) 5.50(±0.32) 0.26 
Observations Light Side 33.94(±2.26) 35.03(±2.35) 0.11 
Prior Emergences 0.84(±0.21) 0.63(±0.17) 0.68 
Elevated Plus Maze    
% Entries in Open Arms 0.49(±0.02) 0.52(±0.02) 0.80 
% Observations in Open Arms 0.53(±0.03) 0.54(±0.03) 0.05 
Entries into Closed Arms 6.42(±0.41) 6.34(±0.35) 0.04 



















12.5 Non-Behavioural Measures 
 The difference in weight (in grams) between treatment and testing (‘adolescence’ and 
‘adulthood’ respectively) was calculated and compared across experimental conditions. Only 
sex had a significant effect on the weight gained during this period, with males gaining over 
150% the weight of females. The mean ±SEM weight gain for each group were: saline = 
82.40±3.88, mephedrone = 87.58 ±3.87, F(1,55) = 1.98, p=0.16; standard = 83.94 ±3.71, 
enriched = 86.16 ±4.09, F(1,55) = 0.68, p=0.41; and male = 102.90 ±2.73, female = 67.72 






















 Experiment 3 examined the teratological properties of mephedrone on anxiety-related 
behaviours, and the potential of environmental enrichment to protect against these effects. 
Subjects were raised in either standard (i.e., ‘impoverished’) or enriched (containing toys or 
objects to stimulate activity and exploration) cages from weaning until behavioural testing 
took place in adulthood (approximately 4 months). During a developmental period analogous 
to mid-late adolescence in humans, subjects were treated with 20mg/kg of mephedrone (or 
saline) once per day, for ten consecutive days, representing a chronic ‘binge-like’ cycle. No 
subsequent manipulations were performed until the subjects reached adulthood, at which time 
they were tested for their degrees of anxiety-related behaviours in the open field, light/dark 
box, and elevated plus maze behavioural testing paradigms. The results generally supported 
both Hypothesis 1 (that subjects treated with mephedrone during adolescence would display 
more anxiety-related behaviours compared to control) and Hypothesis 2 (that subjects raised 
in enriched environments would display fewer anxiety-related behaviours than those raised in 
standard cages). There was also emerging support from one of the tests for Hypothesis 3: that 
environmental enrichment would mitigate the anxiogenic effects of mephedrone (relative to 
the standard caging condition). 
13.1 Open Field Findings  
 13.1.1 Drug effects. Adolescent treatment with mephedrone produced a number of 
significant differences (relative to saline control) when the same subjects were later tested in 
the open field paradigm as adults (i.e., 4 months post-treatment). Ambulation was 
significantly decreased, as was the frequency of rearing behaviours. Conversely, freezing 
behaviours displayed a significant increase following mephedrone treatment. Although these 
differences are indicative of increased anxiety and support Hypothesis 1, they are more 




anxiety is consistent with similar research showing a lasting anxiogenic effect of adolescent 
treatment with other designer drugs, namely benzylpiperazine and MDMA (Aitchison & 
Hughes, 2006; Kolyaduke & Hughes, 2013).  
The remaining open field measures (walking, grooming, centre occupancy and corner 
occupancy) did not show significant differences between saline and mephedrone groups, 
though a visual inspection of the results shows these data to also be in the directions 
predicted by the hypotheses. No firm conclusions can be drawn from these particular 
measures, though it is possible that they reflect an anxiogenic effect of mephedrone 
(Hypothesis 1) that is present but too weak to produce significant differences (i.e., perhaps 
the behavioural teratological effect of acute mephedrone administration diminishes over time 
following cessation of drug administration). 
 13.1.2 Enrichment effects. Those subjects raised in enriched environments displayed 
significantly less walking and freezing behaviours, and more rearing behaviours in the open 
field. These results are indicative of reduced anxiety and support Hypothesis 2. The 
remaining measures were non-significant, though as with the results described above, several 
of the measures were in the predicted direction (e.g., center and corner occupancy were 
suggestive of reduced anxiety). 
 13.1.3 Interaction effects. Some interesting drug × enrichment effects were noted in 
the open field results. Mephedrone significantly decreased ambulation and increased freezing 
behaviours (results indicating more anxiety, as predicted by Hypothesis 1) for subjects raised 
in standard cages but not for those raised in enriched cages. Similarly, although there were no 
significant main effects of mephedrone on the corner occupancy measure, the pattern of 
responding was different for those subjects raised in standard cages versus enriched cages. As 
can be seen visually in Figure 16D, for subjects raised in standard cages, mephedrone 




significant), whereas for subjects raised in enriched cages this effect was reversed. These 
findings tend to support Hypothesis 3 and suggest that environmental enrichment may confer 
some degree of resilience or resistance against the anxiogenic properties of mephedrone.  
 A sex × enrichment interaction was also significant in the open field results. It was 
found that for standard cages, female subjects reared significantly more often (a behaviour 
indicative of less anxiety) than male subjects. In enriched cages however, there was no 
significant difference in rearing behaviours between male and female subjects (though both 
sexes reared more than in standard cages). This finding may suggest that the benefits of 
environmental enrichment are different for males than for females; perhaps that males have 
more to gain from this manipulation than females. 
13.2 Light/Dark Box Findings    
 13.2.1 Drug effects. Following adolescent treatment with either mephedrone or saline 
there were a number of effects and patterns noted in adulthood using the light/dark box 
testing paradigm. Subjects treated with mephedrone made significantly fewer entries into the 
light side of the light/dark box (a behaviour indicative of increased anxiety) compared to 
control subjects. While there were no significant differences found for first emergence 
latency or for time spent in the light side, a visual inspection of the results shows these 
measures to be in the predicted directions as well. Similar to findings in the open field, these 
measures may reflect a degree of anxiety-like behaviour that has lessened over time (since 
drug administration) so that now it is not potent enough to be detected using the current 
methodology. While no firm conclusions can be currently drawn from these measures alone, 
taken together with the number of entries measure, and the open field results, these findings 
suggest support for Hypothesis 1 in that those subjects who were treated with mephedrone 
were more anxious than those in the control group. This conclusion is consistent with 




 The prior/partial entries measure was included as it was thought that it may represent 
a degree of risk assessment behaviour (Arrant et al., 2013). The current results found no 
difference between mephedrone or control groups, suggesting that either this measure (as 
utilised by the current methodology) does not accurately measure risk assessment behaviours, 
or that adolescent mephedrone use does not produce a lasting effect on risk assessment 
behaviours in adults. It is therefore concluded that the latter explanation is more likely to 
apply as significant differences in this response were noted in Experiment 1 that examined 
the acute effects of mephedrone. It may be that these acute effects on risk assessment 
behaviours fade with the acute drug intoxication, or perhaps that risk assessment is 
fundamentally different in adolescents than in adults, so the expression of the effect is 
dependent on the developmental time of exposure. This would be worth exploring in future 
research. 
 13.2.2 Enrichment effects. Subjects raised in enriched environments took less time 
to fully emerge into the light side of the apparatus, made more entries of the light side, and 
spent significantly more time in the light side compared to those raised in standard cages. 
However, only the difference for the latter response was statistically significant. These results 
are suggestive of reduced anxiety in the enriched condition (supporting Hypothesis 2), which 
adds further evidence to previous research that has found environmental enrichment to have 
an anxiogenic effect on rodents (Benaroya-Milshtein et al., 2004; Laviola et al., 2004). 
 Environmental enrichment nearly doubled the occurrence of prior/partial entrances 
into the light side, suggesting that this type of enriched environment may confer an increase 
in cautionary or risk assessment behaviours in subjects. While the noted effect did not reach 
statistical significance, it was very close to achieving significance (p = 0.0507) and may have 




Something interesting appears to be occurring here, and future research may need to adapt the 
current methodology in order to better observe any effect. 
 13.2.3 Interaction effects. An interesting drug × sex × enrichment effect was noted 
for the observations in the light side measure. For female subjects; those raised in standard 
cages showed no significant effect of mephedrone treatment, whereas those subjects raised in 
enriched cages showed a significant decrease in time spent in the light side following 
treatment with mephedrone. For males, this drug × enrichment effect was not found; instead, 
in both standard and enriched cages mephedrone had no significant effect on observations in 
the light side. These results suggest that enrichment mitigated the anxiogenic effect of 
mephedrone (which supports Hypothesis 3) for females but not for males. Combined with the 
sex × enrichment interaction noted in the open field results, this is further evidence that the 
ability of environmental enrichment to mitigate the anxiogenic effects of mephedrone may be 
different for males and females.  
13.3 Elevated Plus Maze Findings 
13.3.1 Drug effects. Adolescent treatment with mephedrone did not have any 
significant effects on the anxiety-related measures of the elevated plus maze when subjects 
were tested in adulthood. The only measure that displayed a significant difference was 
‘entries of the closed arms’, a control measure that was added to assess levels of general 
locomotor activity uncontaminated by anxiety (Cruz et al., 1994). Adolescent treatment with 
mephedrone caused a significant decrease in the number of entries into the closed arms 
relative to the control group. Taken together, these findings indicate that the subjects treated 
with mephedrone were generally less ambulatory in the elevated plus maze than those who 
received saline, though neither groups showed any preference for either the closed arms or 




These findings do not support the hypotheses, and are inconsistent with the results we 
would expect based on similar studies in the literature (Hughes et al., 2015; Pellow et al., 
1985; Silva & Brandao, 2000). However, the current findings are consistent with the results 
observed in Experiment 1, which also found no significant differences on any measures 
except for entries into the closed arms. If the acute exposure to mephedrone did not produce 
significant anxiogenic effects as assessed by this test, then logically such effects would be 
unlikely to appear when tested later in life. Experiment 2 however, did find anxiogenic 
effects of mephedrone in the elevated plus maze and at the same dose used in this study 
(20mg/kg). The acute effects observed in Experiment 2 may not have produced lasting 
teratological effects observable in the current study, though the results of the open field and 
light/dark box tests discussed earlier would refute this. Few conclusions can be drawn from 
the elevated plus maze results, as the findings appear to be inconsistent. It is unclear why this 
is the case, so addressing this issue will be an important facet of any future research. 
13.3.2 Enrichment effects. As with the drug effects discussed above, only the 
‘entries into the closed arms’ measure displayed any significant effects of enrichment. 
Environmental enrichment significantly reduced the number of entries into the closed arms of 
the elevated plus maze, indicating that those subjects raised in enriched environments were 
generally less ambulatory in the elevated plus maze than those raised in standard cages.  
13.4 Sex Differences 
 As with the findings of Experiments 1 and 2, female subjects generally engaged in 
more locomotor and exploratory behaviours than male subjects, in keeping with sex 
differences already acknowledged in previous reports (Kokras & Dalla, 2014). The only 
measure to produce a significant difference however (besides the interaction effects already 
discussed), was ambulation in the open field, where females were significantly more 




13.5 Non-Behavioural Measures 
 Weight was the only non-behavioural measure recorded in this study, with subjects 
being weighed both during treatment (i.e., ‘adolescence’) and again at testing (i.e., 
adulthood). The difference in weight between these two times was calculated, and the only 
significant variable affecting this measure was sex: male subjects gained significantly more 
weight than females. Enrichment did not significantly affect weight gain, nor did drug 
treatment. This latter point may be significant in telling us that chronic mephedrone use 
during adolescence may not impair physical growth and development, although this one 
measure is insufficient to justify any more than hypothesis formulation at present.  
13.6 Limitations and Future Research 
 A number of limitations and ideas for future research have already been discussed in 
this section: the inclusion of a prior/partial emergences measure in the light/dark box may 
represent risk assessment behaviour following acute drug treatment, but the utility and 
validity of this measure when examining chronic or teratological effects remains to be 
explored; the inconsistent findings in the elevated plus maze need to be adequately explained, 
and subsequently remedied (if possible); and weight gain between adolescence and 
adulthood, alone, is not sufficient to generalise any conclusions about physical development. 
 A potential methodological issue with this study, when viewed in the wider context of 
the three Experiments combined, is that in the time between Experiments 2 and 3 the animal 
facility changed the food available to the rats in their home cages. This would seem an 
insignificant change except that the researcher and the animal technicians noted that the 
animals in Experiment 3 appeared smaller than usual. This suspicion was confirmed when 
historical data from a similar experiment conducted in the same lab in 2012 showed that the 
average weight of a subject on the first day of adolescent treatment (PND45) then was 100 




treatment were 130 grams and 85 grams respectively). The animals otherwise appeared to be 
healthy and developing at a normal rate. It is unclear what impact this might have had, if any, 
on the interpretability of the current findings, though the majority of the results suggest that 
this was not a significant confounding variable as statistical differences in the predicted 
ranges were still found. 
 It would be interesting to determine if the behavioural teratological effects of 
mephedrone that were observed in this study are permanent, or if they might fade over time, 
i.e., if the animals were re-tested after another year would the effect still be seen, and if so, 
still as severe? Similarly, would the positive effects conferred by environmental enrichment 
remain if the enrichment were removed? Or if enrichment were only introduced after the 
adolescent mephedrone treatment, could the anxiogenic effects be reversed post-hoc? There 
are a number of ways, and combinations of these two variables that remain to be explored. 
 A number of findings in this study suggest that environmental enrichment’s ability to 
mitigate the anxiogenic effects of adolescent mephedrone use (i.e., Hypothesis 3) differs for 
males and females. This is an interesting discovery that warrants further investigation of why 
this is so, what mechanisms are involved, and what practical implications this may have for 
designing interventions that are effective both for males and for females.  
13.7 Conclusion 
 The results from both the open field and light/dark box tests support Hypothesis 1 
(that chronic mephedrone use during adolescence would result in more anxiety-like 
behaviours when tested later in adulthood), and Hypothesis 2 (that environmental enrichment 
would reduce the frequency of anxiety-like behaviours). A number of significant interactions 
also supported Hypothesis 3 (that environmental enrichment would mitigate the anxiogenic 
effects of mephedrone use during adolescence), though interestingly this effect was found to 




behavioural teratogen when used during adolescence, producing changes in behaviour that 
are long-lasting, if not permanent. This has significant implications for public health as 
adolescence is typically the age when people are most likely to experiment with recreational 
drugs (National Instutute on Drug Abuse, 2014; Spear, 2007). The finding that environmental 
enrichment is capable of reducing or preventing this long-term harm is an exciting prospect 
that may inform how such resilience, and perhaps recovery, could be conferred on people 






















14.0 Summary and Conclusion 
In the ever-changing world of designer drugs, governments, healthcare providers, and 
even researchers seem to constantly be one step behind the drug makers. Users buy these 
drugs, often under the impression that they are safe alternatives to known drugs of abuse, or 
at least without any explicit knowledge that they are unsafe alternatives. Likewise, many 
legislative bodies are seemingly powerless to act on these ever-emerging new designer drugs 
until evidence begins to pile up showing a harmful effect. In many ways, the well-established 
drugs of abuse such as methamphetamine, cocaine, and MDMA, may be considered the safer 
choices in light of the fact that their effects (horrific as they can be) are at least comparatively 
well-documented and understood. When the effects of these drugs are known, this can inform 
policy-makers (who can attempt to control the supply and availability of dangerous drugs), 
healthcare providers (who can better respond to the medical and psychological needs of drug 
users), and consumers (who may elect not to use a drug that has been shown to be unsafe). 
Given the speed and relative ease with which new drugs are constantly being created, it can 
appear to be an ‘uphill battle’ for drug researchers to understand each new compound, but the 
potential for harm resulting from inaction makes the pursuit of such information a vitally 
important and noble goal. 
For all of the reasons described above, the current study sought to increase our 
collective knowledge about the effects of mephedrone; one of the primary compounds 
representing the present generation of designer drugs; the synthetic cathinone derivatives, 
popularly known as ‘bath salts’. Despite first being synthesised nearly 90 years ago, 
mephedrone has only become a popular drug of abuse in the last few years, prompting a need 
for its harmful sequelae to be better known. Research in the last few years has expanded our 
understanding of the pharmacology and toxicology of mephedrone, and we have learned that 




arguably that few studies have been conducted specifically examining the behavioural 
sequelae of mephedrone use. This was the rationale for the current study, which used animal 
models to examine the effects of mephedrone on anxiety-related behaviours in three 
randomised controlled experiments.  
In Experiment 1, 50 male and 50 female rats were administered mephedrone at doses 
of 0 (saline control group), 1, 20, 40, and 60 mg/kg, and then the anxiety-like behaviours of 
the subjects were measured in the open field, light/dark box, elevated plus maze, and novel 
object recognition behavioural testing paradigms. The results of Experiment 1 indicated that 
mephedrone had an anxiogenic effect, and that this effect was generally dose-dependent. 
Interestingly, the dose-response curve was different for males and females, with males 
displaying the predicted inverted ‘U’ shaped curve (anxiety increased with higher doses of 
mephedrone up until 20mg/kg, then decreased), whereas females instead displayed a linear 
increase (as mephedrone dose increased, so too did anxiety-related behaviours. It was 
hypothesised that this drug × sex interaction was due to differences in the expression of 
stereotypy behaviours induced by mephedrone. This was subsequently explored in 
Experiment 2. 
Experiment 2 followed a similar methodology to Experiment 1 (using mephedrone 
doses of 0, 1, 10, and 20 mg/kg) to examine anxiety-related behaviours in the open field and 
elevated plus maze, and additionally included some measures designed to assess stereotypy 
behaviours. The results again showed mephedrone to produce a dose-dependent anxiogenic 
effect, and also a dose-dependent effect on stereotypy (the higher the dose of mephedrone, 
the greater the frequency of stereotypy behaviours observed). As predicted, these stereotypy 
behaviours were expressed differently for males and females, with males typically displaying 
more non-ambulatory stereotypies (such as head swaying), and females, more movement-




the expression of behaviours (as opposed to the degree to which the behaviours are 
performed), make it very difficult, if not impossible, for any firm conclusions to be drawn 
regarding sex differences in the underlying concept (e.g., “Are males more anxious than 
females, overall?”). The researcher noted that stereotypy, as a potential confound to anxiety-
related measures, may be inextricably connected to the observable effects of anxiety, and as 
such requires consideration in the interpretation of results from these studies (and others like 
them). 
Experiment 3 looked at the potential for mephedrone to cause lasting effects on 
anxiety-related behaviours when used chronically during the developmental period of 
adolescence. The results showed that following chronic, adolescent use of mephedrone, more 
anxiety-like behaviours were still evident later in life when compared to a saline control 
group. This suggests a behavioural teratological effect of mephedrone that can persist beyond 
acute cessation. As the secondary aim of the experiment, it was also observed that the noted 
effect on anxiety-related behaviours was largely mitigated by environmental enrichment, 
though interestingly, while both males and females enjoyed this increased ‘resilience’, 
enrichment conferred its benefits differently for both sexes. It is unclear from this study why 
males and females would differ in their accrued advantages following environmental 
enrichment, though realising that the two sexes have such different responses to this 
intervention may prove vital to any practical applications that may result from such early 
research. 
The primary aims of the study were accomplished over the three experiments, but 
overall, perhaps the most impressive and interesting findings have been those of the sex 
differences and drug × sex interaction effects. The results of this study add further support to 
a growing and compelling movement within the animal research field to including both male 




current study, many of the most important and useful findings would have been missed, and 
the conclusions less generalisable.  
The findings of these three experiments raise some interesting implications for the 
human users of mephedrone. That these drugs can cause anxiety and related symptoms has 
been established before in case reports and some survey-based research, whereas now we 
have some evidence to suggest that the dose of mephedrone ingested can dependently 
increase the magnitude of the given effect, and that it may do so differently for men and for 
women. The sex differences and drug × sex interactions found in the current study may be 
some of the more important findings in terms of influencing our understanding of 
mephedrone’s effects in humans; the results suggest that while men and woman likely both 
experience a dose-dependent effect of mephedrone (generally speaking, higher doses produce 
more of a given effect), the overt expression of the effects may differ between the sexes, with 
females tending towards more active, movement-based behaviours compared to males. 
Practically speaking, this may translate to men displaying more internalising behaviours 
(such as depression, psychosis, and paranoia), whereas women may display more 
externalising behaviours (such as hyperactivity, and self-mutilation). Based on the current 
findings, females also appear to be more sensitive to the hyperthermic effects of mephedrone, 
which suggests an increased risk and susceptibility (compared to males) to some of the more 
dangerous physiological sequelae of mephedrone use. 
Another interesting implication is that of the enrichment findings from Experiment 3. 
That environmental enrichment was able to mitigate some of the negative consequences of 
chronic, adolescent, mephedrone use, is an exciting and promising feature that may lead to 
tangible therapeutic solutions for treating drug abuse disorders in humans. More research is 
needed here though to discover how environmental enrichment confers its benefits (i.e., what 




enrichment protect against later drug exposure, or does post-hoc enrichment reverse the 
subsequent effects of exposure?).  
The findings of these three experiments should be viewed as a beginning to our 
understanding of the behavioural effects of mephedrone use; there are many areas left still to 
be explored, and many explanations that remain yet to be found. An obvious limitation of the 
current study is the lack of any neurochemical assays, biological analyses, or investigations 
into potential mechanisms of action for the observed behavioural effects. In many ways the 
current study has opened more avenues for exploration than it has closed, and it was because 
of this nearly limitless scope that the researcher chose to confine the investigation exclusively 
to behavioural analyses. Given the present findings, and some of the questions subsequently 
raised, it would be interesting for future research to examine the neuro-biological aspects of 
the current results, in order to provide a more balanced view, and to potentially infer some 
causative mechanisms.     
It could be argued that the real ‘war on drugs’ is not being fought by law enforcement 
officials on the front line, but by drug researchers in their laboratories. Currently the only 
defence we have against the ever-increasing waves of new designer drugs is information: the 
more we know about what we are facing the better equipped we are to deal with the threat 
that they pose to individuals and to society. With new synthetic drugs being created all the 
time, it may seem like a losing and costly battle to research every new compound; but it must 
be remembered, amongst all the science, that these drugs have a very real effect on real 
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Open Field Record Sheet 
 
 
Rat ID:________  Adolescent drug condition:________ Rat sex:______  Date:_______ 




Transitions                         =  ______    Centre squares (6, 7, 10, 11) =  ______ 
 
Corner squares (1, 4, 13, 16) =  ______    Rearing (R)                             =  ______ 
 
Walking (W)                  =  ______    Grooming (G)              =  ______   
  
Freezing (F)                    =  ______ # faecal boluses  =  ______ 
 
Transitions 1-60                       =  ______    Transitions 61-100                 =  ______  
 
 1)     
2)     
3)     
4)     
5)     
6)     
7)     
8)     
9)     
10)   
 
  
11)     
12)     
13)     
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15)     
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Elevated Plus Maze Record Sheet 
 
Rat/ID__________________      Group_______________     Sex_______ 
Elevated plus maze 
Occupying arms 1, 2, 3, 4 (Specify which are the OPEN and which are the CLOSED arms) 
1)      
2)      
3)      
4)      
5)      
6)      
7)      
8)      
9)      
10)    
2.5 min 
  
11)      
12)      
13)      
14)      
15)      
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17)      
18)      













Observations: arm 1 =______                 arm 2 =______                 arm 3 =______                 arm 4 =______:  
TOTAL OPEN arms = ________;                                                           TOTAL CLOSED arms  = ________;   
Entries arm 1______________________________________________________________________________ 
Entries arm 2______________________________________________________________________________ 
Entries arm 3______________________________________________________________________________ 
Entries arm 4______________________________________________________________________________ 
TOTAL entries OPEN arms= ________;                                   TOTAL entries CLOSED arms = ________;   





Light/Dark Box Record Sheet 
 
Light-dark box behaviour 




1st emergence latency (in seconds)         = _________________ 
 
Partial entries into LIGHT side                   = _________________ 
 
Entries of LIGHT side                                   = _________________ 
 
Observations/100 in LIGHT side    = _________________ 
 
# faecal boluses                 = _________________ 
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Novel Object Recognition Record Sheet 
 
Novel object recognition: Rat/ID__________________      Group_______________     Sex_______ 
[Proximity: <2cm from object.  Novel object = N,  familiar object = F] 
 
 1st min 2nd min 3rd min 4th min 5th min 
 Proximity 
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Photos of observed adverse effects following mephedrone treatment. 
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Photos from enriched and standard caging conditions. 
 
   
      




Figure I2. Example of an “impoverished” cage from the standard condition. 
 
